<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">107742</article-id>
<article-id pub-id-type="doi">10.7554/eLife.107742</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.107742.2</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.3</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Immunology and Inflammation</subject>
</subj-group>
</article-categories><title-group>
<article-title>Xcr1<sup>+</sup> type 1 conventional dendritic cells are essential mediators for atherosclerosis progression</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Li</surname>
<given-names>Tianhan</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">#</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Lu</surname>
<given-names>Liaoxun</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Qiu</surname>
<given-names>Juanjuan</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dong</surname>
<given-names>Xin</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Le</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Kexin</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gu</surname>
<given-names>Yanrong</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Binhui</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jia</surname>
<given-names>Tingting</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lawrence</surname>
<given-names>Toby</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Malissen</surname>
<given-names>Marie</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Guixue</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Rong</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Hui</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1340-9342</contrib-id>
<name>
<surname>Malissen</surname>
<given-names>Bernard</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<email>bernardm@ciml.univ-mrs.fr</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9174-4037</contrib-id>
<name>
<surname>Liang</surname>
<given-names>Yinming</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a5">5</xref>
<email>yinming.liang@gris.org.cn</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7810-9941</contrib-id>
<name>
<surname>Zhang</surname>
<given-names>Lichen</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<email>zhanglichen@gris.org.cn</email>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/038hzq450</institution-id><institution>School of Basic Medicine, Xinxiang Medical University</institution></institution-wrap>, <city>Xinxiang</city>, <country country="CN">China</country></aff>
<aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/038hzq450</institution-id><institution>School of Medical Technology, Xinxiang Medical University</institution></institution-wrap>, <city>Xinxiang</city>, <country country="CN">China</country></aff>
<aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035xkbk20</institution-id><institution>Centre d’Immunologie de Marseille-Luminy, INSERM, CNRS, Aix-Marseille Université</institution></institution-wrap>, <city>Marseille</city>, <country country="FR">France</country></aff>
<aff id="a4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/023rhb549</institution-id><institution>Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University</institution></institution-wrap>, <city>Chongqing</city>, <country country="CN">China</country></aff>
<aff id="a5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02a5vfy19</institution-id><institution>Center of Disease Model and Immunology, Hunan Academy of Chinese Medicine</institution></institution-wrap>, <city>Changsha</city>, <country country="CN">China</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Yona</surname>
<given-names>Simon</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>The Hebrew University of Jerusalem</institution>
</institution-wrap>
<city>Jerusalem</city>
<country country="IL">Israel</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Rath</surname>
<given-names>Satyajit</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>Indian Institute of Science Education and Research (IISER)</institution>
</institution-wrap>
<city>Pune</city>
<country country="IN">India</country>
</aff>
</contrib>
</contrib-group>
<author-notes><fn id="n1" fn-type="equal"><label>#</label><p>These authors contributed equally to this work.</p></fn>
<fn fn-type="coi-statement"><p>Competing interests: No competing interests declared</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2025-07-07">
<day>07</day>
<month>07</month>
<year>2025</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2025-08-15">
<day>15</day>
<month>08</month>
<year>2025</year>
</pub-date>
<volume>14</volume>
<elocation-id>RP107742</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2025-05-22">
<day>22</day>
<month>05</month>
<year>2025</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2025-05-28">
<day>28</day>
<month>05</month>
<year>2025</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2025.05.23.655779"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2025-07-07">
<day>07</day>
<month>07</month>
<year>2025</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.107742.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.107742.1.sa2">eLife Assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.107742.1.sa1">Reviewer #1 (Public review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.107742.1.sa0">Reviewer #2 (Public review):</self-uri>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2025, Li et al</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Li et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-107742-v2.pdf"/>
<abstract>
<title>Abstract</title><sec>
<title>Background</title>
<p>Atherosclerosis is characterized by lipid accumulation within plaques, leading to foam cell formation and an inflammatory response within the aortic lesions. Lipid disorders have been extensively investigated, however the cellular and molecular mechanisms that trigger the inflammatory response in atherosclerotic plaques remain far from being fully understood. Xcr1<sup>+</sup> cDC1 cells are newly identified antigen-presenting cells in activating immune cells. However, the role of cDC1 cells in the development of atherosclerosis remains highly controversial.</p>
</sec>
<sec>
<title>Results</title>
<p>We first confirmed the presence of cDC1 within human atherosclerotic plaques and discovered a significant association between the increasing cDC1 numbers and atherosclerosis progression in mice. Subsequently, we established Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice, a novel and complex genetic model, in which cDC1 was constitutively depleted <italic>in vivo</italic> during atherosclerosis development. Intriguingly, we observed a notable reduction in atherosclerotic lesions in hyperlipidemic mice, alongside suppressed T cell activation of both CD4<sup>+</sup> and CD8<sup>+</sup> subsets in the aortic plaques. Notably, aortic macrophages and serum lipid levels were not significantly changed in the cDC1-depleted mice. Single-cell RNA sequencing revealed heterogeneity of Xcr1<sup>+</sup> cDC1 cells across the aorta and lymphoid organs under hyperlipidemic conditions. As Xcr1 is the sole receptor for Xcl1, we next explored to target Xcr1<sup>+</sup> cDC1 cells via Xcl1 by establishing Xcl1 and ApoE deficient mice. Xcl1 knockout mice exhibited decreased atherosclerotic plaque formation and reduced aortic cDC1 accumulation, indicating that Xcl1 contributes to cDC1-mediated atherosclerotic lesion development.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>Our results reveal crucial roles of cDC1 in atherosclerosis progression and provide insights into the development of immunotherapies by targeting cDC1 through Xcl1.</p>
</sec>
</abstract>
<funding-group>
<award-group id="funding-1">
<funding-source>
<institution-wrap>
<institution>Science and Technology Innovation Program of Hunan Province</institution>
</institution-wrap>
</funding-source>
<award-id>2023DK2005</award-id>
</award-group>
<award-group id="funding-1a">
<funding-source>
<institution-wrap>
<institution>Science and Technology Innovation Program of Hunan Province</institution>
</institution-wrap>
</funding-source>
<award-id>2024RC1071</award-id>
</award-group>
<award-group id="funding-1b">
<funding-source>
<institution-wrap>
<institution>Science and Technology Innovation Program of Hunan Province</institution>
</institution-wrap>
</funding-source>
<award-id>2022RC1223</award-id>
</award-group>
<award-group id="funding-2">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>32170879</award-id>
</award-group>
<award-group id="funding-2a">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>82301972</award-id>
</award-group>
<award-group id="funding-3">
<funding-source>
<institution-wrap>
<institution>Science and Technology Department of Henan Province</institution>
</institution-wrap>
</funding-source>
<award-id>242102310030</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>This version employs clean files (without tracked changes), with methods sections, appendices, and supplementary figures and tables fully incorporated into the main manuscript file.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Atherosclerosis is a chronic inflammatory disease that affects the large and medium-sized arteries, and it is the leading cause of cardiovascular mortality and morbidity worldwide [<xref ref-type="bibr" rid="c1">1</xref>]. Atherosclerosis is a complex pathological process during which lipid-laden phagocytes such as macrophages, along with lymphocytes and dendritic cells, accumulate in the plaque [<xref ref-type="bibr" rid="c2">2</xref>]. Mounting evidence from animal models and human studies demonstrates involvement of both the innate and adaptive immunity in the development of atherosclerosis [<xref ref-type="bibr" rid="c3">3</xref>–<xref ref-type="bibr" rid="c5">5</xref>]. In healthy arteries, DCs are typically present in the subendothelial space and work in the front line of immune surveillance [<xref ref-type="bibr" rid="c6">6</xref>, <xref ref-type="bibr" rid="c7">7</xref>], and small portion of resident vascular DCs are localized in the adventitia. Various studies have demonstrated that DCs accumulated in the advanced atherosclerotic lesions in both humans and animal models [<xref ref-type="bibr" rid="c8">8</xref>–<xref ref-type="bibr" rid="c11">11</xref>]. Recently, several phenotypically and functionally distinct vascular DCs have been identified in mouse and human atherosclerotic lesions [<xref ref-type="bibr" rid="c12">12</xref>]. Xcr1<sup>+</sup> type 1 conventional dendritic cells (Xcr1<sup>+</sup> cDC1) (also known as CD8<sup>+</sup> DC or CD103<sup>+</sup> DCs) has been recognized for its role in cross-presentation and activating naive CD8<sup>+</sup> T cells, and are critical for anti-viral and anti-tumor immune responses [<xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c14">14</xref>]. Owing to the challenges associated with obtaining a model for specific cDC1 depletion <italic>in vivo</italic>, previous studies investigating the role of cDC1 cells in atherosclerosis using various knockout mice have produced conflicting results [<xref ref-type="bibr" rid="c15">15</xref>–<xref ref-type="bibr" rid="c19">19</xref>]. It is important to note that previous Cre lines developed to achieve specific Cre expression in cDC1s still led to leakiness in recombinase activity outside of cDC1s, as demonstrated in previous publications [<xref ref-type="bibr" rid="c20">20</xref>, <xref ref-type="bibr" rid="c21">21</xref>]. Moreover, scant mechanistic understanding regarding the regulation of cDC1 activity during atherosclerosis has been reported. Therefore, developing a more specific mouse model for cDC1 is essential for elucidating its precise role in atherosclerosis. Here, we established a novel Cre line Xcr1<sup>Cre-Gfp</sup> mice and did not observe any leakiness of Cre activity, and further experiments revealed that specific depletion cDC1 attenuates atherosclerosis development by inhibiting both CD4<sup>+</sup> and CD8<sup>+</sup> T cell activation in hyperlipidemic Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice.</p>
<p>The origin of phagocytes within the atherosclerotic plaques has been controversial. Studies have shown that the major contribution of macrophages in the aortic plaque is recruited from the circulation, while other studies have emphasized the significance of local proliferation [<xref ref-type="bibr" rid="c22">22</xref>, <xref ref-type="bibr" rid="c23">23</xref>]. Tissue-resident dendritic cells inside the plaques have been well documented [<xref ref-type="bibr" rid="c24">24</xref>, <xref ref-type="bibr" rid="c25">25</xref>], regardless of the fact that the contribution and origin of Xcr1<sup>+</sup> cDC1 have not been appropriately addressed. To understand the origin of Xcr1<sup>+</sup> cDC1 inside the plaque, we performed bone marrow transplantation using Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> mice as donors and found that in ApoE<sup>−/−</sup> recipient mice placed on a high-fat diet (HFD), cDC1 cells were completely absent in the aortas. Therefore, our experiments have elucidated that cDC1 cells in the atherosclerotic plaques originate from the bone marrow. Further single cell RNA sequencing illustrated that notable differences in Xcr1<sup>+</sup> cDC1 cells are discovered among the aorta, spleen, and lymph nodes. <italic>Ccr2</italic>, <italic>Sept3</italic> and <italic>Cldnd1</italic> were highly expressed in Xcr1<sup>+</sup> cDC1 cells from aorta compared with that from spleen and lymph nodes.</p>
<p>We further aimed to ascertain whether cDC1 can be modulated by targeting the chemokine Xcl1, which is a ligand of Xcr1. Considering the vital role that Xcr1<sup>+</sup> cDC1 plays in the progression of atherosclerosis and the therapeutic potential of manipulating their functions via chemokines[<xref ref-type="bibr" rid="c26">26</xref>], comprehending the feasibility of targeting Xcl1 holds considerable promise for developing novel therapeutic approaches to halt the advancement of atherosclerosis. We conducted further studies using Xcl1<sup>−/−</sup> ApoE<sup>−/−</sup> double knockout mice to assess the pathological grade of atherosclerotic lesions. Our data indicated that the knockout of Xcl1 led to a mild yet significant reduction of cDC1 cells in the aorta. However, strikingly, when compared to the ApoE<sup>−/−</sup> control mice, the Xcl1<sup>−/−</sup> ApoE<sup>−/−</sup> mice exhibited a markedly decreased severity of the atherosclerotic lesions, to an extent comparable to that observed in cDC1-depleted Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice.</p>
<p>Therefore, our study which employed genetic models to deplete Xcr1<sup>+</sup> cDC1 <italic>in vivo</italic> in hyperlipidemic mice, has unequivocally determined the essential role of this specific cell type in the development of atherosclerosis. Besides their well-established role in cross-presentation to CD8<sup>+</sup> T cells, recent studies have shown Xcr1<sup>+</sup> cDC1 cells also engage with CD4<sup>+</sup> T cells to augment CD8<sup>+</sup> T cell responses [<xref ref-type="bibr" rid="c20">20</xref>, <xref ref-type="bibr" rid="c27">27</xref>]. Our data showing Xcr1<sup>+</sup> cDC1-dependent CD4 and CD8 T cell activation in atherosclerotic plaques is in line with the new paradigm for cDC1s as a platform for both CD4 and CD8 T cell responses in the novel context of atherosclerosis.</p>
<p>Most importantly, we have successfully demonstrated that targeting the chemokine Xcl1, the ligand of Xcr1, can effectively inhibit atherosclerosis. These novel findings hold the potential to forge a novel trajectory for therapeutic interventions within the field of atherosclerosis, presenting promising prospects for better understanding and treatment of this disorder.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Progressive accumulation of Xcr1<sup>+</sup> cDC1 cells in advanced atherosclerotic lesions in human and mice</title>
<p>Dendritic cells are present in healthy arteries and accumulate within atherosclerotic lesions, participating in various pathogenic and protective mechanisms during atherogenesis [<xref ref-type="bibr" rid="c28">28</xref>, <xref ref-type="bibr" rid="c29">29</xref>]. However, the intra-plaque dynamics of cDC1 and their contribution to atherosclerosis remain undetermined. Using the archived specimens of paraffin-embedded human atherosclerotic arteries from our previous study [<xref ref-type="bibr" rid="c30">30</xref>], we examined the Xcr1<sup>+</sup> dendritic cells in human atherosclerotic plaques. As shown in <xref rid="fig1" ref-type="fig">Figure 1A</xref> and <xref rid="fig1" ref-type="fig">1B</xref>, Xcr1<sup>+</sup> dendritic cells were significantly more abundant in the plaque area of the human femoral artery compared to that in the plaque-free area. Similarly, the immunofluorescence staining results using specific antibodies for Xcr1 and CD11c revealed that Xcr1<sup>+</sup>CD11c<sup>+</sup> dendritic cells accumulated in the plaques of the aortic root in ApoE<sup>−/−</sup> mice that were placed on a HFD for 16 weeks (<xref rid="fig1" ref-type="fig">Figure 1C</xref> and <xref rid="fig1" ref-type="fig">1D</xref>). Sample preparations entailed sectioning and appropriate fixation of the aortic root tissues, which were described in greater detail in the Methods and Materials section. To further elucidate the dynamics of Xcr1<sup>+</sup> cDC1 cells within the plaque during the progression of atherosclerosis, we carried out immunohistochemical analyses of these cells in the lesioned aortic root (<xref rid="fig1" ref-type="fig">Figure 1E</xref>). The area positive for Xcr1 expression was quantified at 8-week on a normal diet (ND), 8-week on HFD, 12-week on HFD and 16-week on HFD, respectively. Quantitative analysis was conducted using image processing software, revealing a continuous accumulation of Xcr1<sup>+</sup> cDC1 cells in the lesioned area as the disease progressed (<xref rid="fig1" ref-type="fig">Figure 1F</xref>). Therefore, our experiments provided data indicating the enrichment of Xcr1<sup>+</sup> cDC1 cells in aortic lesions in both humans and mice, and demonstrated that the accumulation of Xcr1<sup>+</sup> cDC1 cells was significantly greater during the progression of atherosclerosis.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Progressive accumulation of Xcr1<sup>+</sup> cDC1 cells in human and mouse advanced atherosclerotic lesions</title>
<p><bold>A</bold>, Representative images of immunohistochemical staining demonstrate Xcr1 expression in normal areas and plaque areas of the femoral artery from three cardiovascular disease patients. <bold>B</bold>, Quantitative analysis of the Xcr1-positive area in normal area and plaque regions. <bold>C</bold>, Representative immunofluorescence images depict DAPI (blue), Xcr1 (green) and CD11c (red) within the lesions of aortic root of ApoE<sup>−/−</sup> mice fed with 16-week ND or HFD. <bold>D</bold>, Quantitative analysis of Xcr1 and CD11c double positive area in lesion area (n = 6). Scale bars, 100 μm. <bold>E</bold>, Representative images depicting immunohistochemical staining of Xcr1 in lesions of the aortic root of ApoE<sup>−/−</sup> mice fed a HFD for varying durations. <bold>F</bold>, Quantitative analysis of the Xcr1-positive area in the lesion regions. (8-week HFD, n = 11; 12-week HFD, n = 15; 16-week HFD, n = 29). Data represent as mean ± SEM. * <italic>P</italic>&lt;0.05. *** <italic>P</italic>&lt;0.001.**** <italic>P</italic>&lt;0.0001.</p></caption>
<graphic xlink:href="655779v3_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2b">
<title>Xcr1<sup>Cre-Gfp</sup> is selectively expressed in cDC1</title>
<p>To understand the role of Xcr1<sup>+</sup> cDC1 in regulating the development of atherosclerosis, we established the Xcr1<sup>Cre-Gfp</sup> ApoE<sup>−/−</sup> mice in which the Cre recombinase and eGFP was co-expressed under the control of endogenous Xcr1 promoter following start codon (<xref rid="figS1" ref-type="fig">Figure S1</xref>). This new Cre line differs from a previous design in which Cre recombinase was expressed via IRES linkage at the 3’ UTR and leaked expression of Cre was frequently observed [<xref ref-type="bibr" rid="c20">20</xref>, <xref ref-type="bibr" rid="c31">31</xref>]. To verify the fidelity of Cre expression under hyperlipidemic condition, we used hyperlipidemic ApoE<sup>−/−</sup> mice as recipient mice and used bone marrow cells from Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-tdRFP</sup> mice as donors for the bone marrow transplantation (<xref rid="fig2" ref-type="fig">Figure 2A</xref>). In Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-tdRFP</sup> mice, the presence of Cre protein would turn on the expression of tdRFP as a reporter for the activity of Cre recombinase [<xref ref-type="bibr" rid="c32">32</xref>]. Remarkably, we found that the expression of tdRFP was exclusively present in Xcr1<sup>+</sup> cDC1 when mice were fed a HFD for 16 weeks in the bone marrow transplanted mice, and the Cre recombinase activity was not detectable in non-cDC1 cells (<xref rid="fig2" ref-type="fig">Figure 2B</xref> and <xref rid="fig2" ref-type="fig">2C</xref>).</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Selective expression of Xcr1<sup>Cre-Gfp</sup> in cDC1 cells.</title>
<p><bold>A</bold>, Diagram illustrating the bone marrow transfer process. <bold>B</bold> and <bold>C</bold>, Representative flow cytometric analysis and corresponding quantification of GFP<sup>+</sup>RFP<sup>+</sup> in cDC1 and non-cDC1 populations within the cDC1 and non-cDC1 populations of the spleen. These data were obtained from ApoE<sup>−/−</sup> mice that had received bone marrow transplants from either WT or Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-RFP</sup> donors and were maintained on a HFD for 16 weeks (WT, n = 4; Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-RFP</sup>, n = 3). <bold>D</bold> and <bold>E</bold>, Representative flow cytometric analysis and quantification of the percentage of GFP<sup>+</sup> cells among pDC, cDC1 and cDC2 cells populations in the spleen. <bold>F</bold>, Quantification of the percentage of pDC, cDC1 and cDC2 cells in spleen. (D-F, ApoE<sup>−/−</sup>, Xcr1<sup>Cre-Gfp</sup> ApoE<sup>−/−</sup> and Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice fed with a HFD for 16 weeks, n = 3). Data represent as mean ± SEM. **** <italic>P</italic>&lt;0.0001; NS, non-significant.</p></caption>
<graphic xlink:href="655779v3_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>To determine the specificity of GFP expression originating from Xcr1<sup>Cre-Gfp</sup> genetic modification, we examined the GFP levels in three populations of DCs, namely pDC, cDC1, and cDC2 cells, from the spleen of Xcr1<sup>Cre-Gfp</sup> ApoE<sup>−/−</sup> mice that were fed a HFD for 16 weeks. As expected, we found that the GFP expression was stringently restricted to cDC1 cells (<xref rid="fig2" ref-type="fig">Figure 2D</xref> and <xref rid="fig2" ref-type="fig">2E</xref>). In parallel, we compared the GFP expression in Xcr1<sup>+</sup> cDC1-depleted mice that were fed a HFD for 16 weeks. Such cDC1-depleted Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice were obtained by crossing Xcr1<sup>Cre-Gfp</sup> ApoE<sup>−/−</sup> mice with Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice. Strikingly, we observed a complete loss of GFP-positive cells and Xcr1<sup>+</sup> cDC1 cells in Xcr1<sup>+</sup> cDC1-depleted mice (<xref rid="fig2" ref-type="fig">Figure 2D</xref> and <xref rid="fig2" ref-type="fig">2F</xref>). We also examined DCs, including pDCs, cDC1, and cDC2, in the lymph nodes and spleens of Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> and ApoE<sup>−/−</sup> mice maintained on a ND for 7 weeks. The flow cytometric analyses also confirmed the absence of Xcr1<sup>+</sup> cDC1 population in Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice (<xref rid="figS2" ref-type="fig">Figure S2</xref>). Collectively, these data suggest that Cre recombinase activity was selectively confined to cDC1 cells, and no leakiness was observed in lineages other than the Xcr1<sup>+</sup> cDC1 population. We also demonstrated that Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice constitute a desirable model for exploring the role of cDC1 in atherosclerosis.</p>
</sec>
<sec id="s2c">
<title>The specific depletion of Xcr1<sup>+</sup> cDC1 cells significantly alleviates atherosclerosis without influencing the lipid profile and the number of intra-plaque macrophages</title>
<p>To investigate the role of cDC1 cells in atherosclerosis, both Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> and the control ApoE<sup>−/−</sup> mice were subjected to a HFD for 16 weeks. The ORO staining results demonstrated that the size of lesion in both descending aorta and aortic root was significantly smaller in Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice compared with ApoE<sup>−/−</sup> control mice (12.82% <italic>vs</italic> 6.01% in descending aorta; 39.25% <italic>vs</italic> 33.57% in ORO-stained aortic root) (<xref rid="fig3" ref-type="fig">Figure 3A-D</xref>). Given that macrophages play a pivotal role in the development and progression of atherosclerotic lesions, particularly within the necrotic core [<xref ref-type="bibr" rid="c33">33</xref>, <xref ref-type="bibr" rid="c34">34</xref>], we next investigated macrophage involvement in the aorta using IHC and flow cytometry. Interestingly, no significant differences were observed in the necrotic core area of the aortic root between Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice and ApoE<sup>−/−</sup> control mice (<xref rid="fig3" ref-type="fig">Figure 3E</xref> and <xref rid="fig3" ref-type="fig">3F</xref>). Similarly, subsequent flow cytometry analyses and IHC results revealed comparable proportions of F4/80<sup>+</sup> CD11b<sup>+</sup> macrophages in the aorta, as well as similar percentages of CD68-positive macrophages in the aortic lesions between the two groups of mice (<xref rid="fig3" ref-type="fig">Figure 3G-J</xref>). Furthermore, since dyslipidemia is a key characteristic of HFD-treated ApoE<sup>−/−</sup> mice [<xref ref-type="bibr" rid="c35">35</xref>, <xref ref-type="bibr" rid="c36">36</xref>], it is critical to assess body weight and lipid profiles in both groups. Our results indicated no significant differences in body weight or levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) between the two groups (<xref ref-type="fig" rid="figS3">Figure S3A-B</xref>). Additionally, ORO staining of the liver revealed no significant differences either (<xref ref-type="fig" rid="figS3">Figure S3C-D</xref>). Taken together, these results suggested that specific depletion of cDC1 attenuated atherogenesis without affecting lipid status or macrophagic accumulation in aortic lesions.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Specific depletion of Xcr1<sup>+</sup> cDC1 cells in ApoE<sup>−/−</sup> mice reduces atherosclerosis progression with no effect on macrophages.</title>
<p><bold>A</bold>, ORO staining of the descending aortas. Scale bar, 5 mm. <bold>B</bold>, Quantification of the lesion area in the descending aorta (ApoE<sup>−/−</sup> mice, n = 9; Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice, n = 6). <bold>C</bold>, ORO and H&amp;E staining of the aortic roots of representative mice from each group. <bold>D</bold>, Quantification of lesion area in the aortic root. (ApoE<sup>−/−</sup> mice, n = 7; Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice, n = 8). Scale bar, 200 μm. <bold>E</bold> and <bold>F</bold>, H&amp;E staining and quantification of necrotic core area in the lesions of aortic root. (ApoE<sup>−/−</sup> mice, n = 7; Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice, n = 8). Scale bar, 200 μm. <bold>G</bold> and <bold>H</bold>, Representative flow cytometric analysis and quantification of macrophages in the aorta. (ApoE<sup>−/−</sup> mice, n = 8; Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice, n = 6). <bold>I</bold> and <bold>J,</bold> Representative immunohistochemical staining images of CD68 and quantification of CD68 positive area in the lesions of the aortic root. (ApoE<sup>−/−</sup> mice, n = 6; Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice, n = 8). Scale bar, 100 μm. ApoE<sup>−/−</sup> and Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice were fed on a 16-week HFD to develop atherosclerosis. Data represent as mean ± SEM. NS, non-significant. ** <italic>P</italic>&lt;0.01. *** <italic>P</italic>&lt;0.001.</p></caption>
<graphic xlink:href="655779v3_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2d">
<title>Specific depletion of cDC1 attenuates the development of atherosclerosis by modulating the activation of T cell in ApoE<sup>−/−</sup> mice</title>
<p>T cells are among the critical drivers of the pathogenesis of atherosclerosis, and therefore, the triggers of T cell activation in aortic plaques are of great interest for controlling disease progression [<xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c37">37</xref>, <xref ref-type="bibr" rid="c38">38</xref>]. We initially analyzed the cDC1 cells through flow cytometry in both Xcr1<sup>+</sup> cDC1 depleted mice and control mice. In the Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice that were fed a HFD for 16 weeks, we observed a total absence of Xcr1<sup>+</sup> cDC1 in the aorta, lymph nodes, and spleen (<xref rid="fig4" ref-type="fig">Figure 4A-C</xref> and <xref rid="figS4" ref-type="fig">Figure S4</xref>). Subsequently, we assessed T cell phenotype in the two groups of mice. While neither the frequencies nor absolute counts of aortic CD4<sup>+</sup> and CD8<sup>+</sup> T cells differed significantly between two groups of mice (<xref rid="fig4" ref-type="fig">Figure 4D-F</xref>), CD69 frequency and CD44 MFI (Mean Fluorescence Intensity), the T cell activation markers, were significantly reduced in both CD4<sup>+</sup> and CD8<sup>+</sup> T cells from Xcr1<sup>+</sup> cDC1 depleted mice compared to controls (<xref rid="fig4" ref-type="fig">Figure 4G</xref> and <xref rid="fig4" ref-type="fig">H</xref>). Interestingly, such decreased frequencies of CD69<sup>+</sup> T cells were only observed in aortic lesions but not in lymphoid organs such as lymph nodes and the spleen in the Xcr1<sup>+</sup> cDC1 depleted mice (<xref ref-type="fig" rid="figS5">Figure S5A-B</xref> and <xref ref-type="fig" rid="figS5">S5D-E</xref>). We further analyzed the absolute numbers of CD8<sup>+</sup> and CD4<sup>+</sup> T cells in the spleen and lymph nodes and found that the absolute numbers of CD8<sup>+</sup> and CD4<sup>+</sup> T cells were markedly reduced in the spleen but not in the lymph nodes in Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice compared to those in ApoE<sup>−/−</sup> mice (<xref ref-type="fig" rid="figS5">Figure S5C</xref> and <xref ref-type="fig" rid="figS5">S5F</xref>). Absence of cDC1 also resulted in reduced frequencies of CD8<sup>+</sup> T cells in both spleen and lymph nodes in hyperlipidemic mice. We also analyzed T cell populations in the lymph nodes and spleen in two groups of mice that were fed a ND and found that the frequencies of CD8<sup>+</sup> T cells were significantly decreased in the lymph nodes of Xcr1<sup>+</sup> cDC1 depleted mice (<xref ref-type="fig" rid="figS6">Figure S6A-B</xref>). More importantly, the frequencies of CD44<sup>high</sup> CD62L<sup>low</sup> activated memory cells within the CD8<sup>+</sup> subsets in both the spleen and lymph nodes were significantly lower than those in the ApoE<sup>−/−</sup> control mice (<xref ref-type="fig" rid="figS6">Figure S6A-D</xref>). However, in the CD4<sup>+</sup> subsets, such frequencies of CD44<sup>high</sup> CD62L<sup>low</sup> activated cells were comparable in the lymph nodes but marginally lower in the spleen (<xref ref-type="fig" rid="figS6">Figure S6A-D</xref>). It is important to note that the decreased absolute number of CD8<sup>+</sup> T cells in the spleen in Xcr1<sup>+</sup> cDC1 depleted mice was only observed in HFD groups but not in ND groups (<xref ref-type="fig" rid="figS5">Figure S5F</xref> and <xref ref-type="fig" rid="figS6">Figure S6F</xref>). Our data indicate that in aortic plaques, Xcr1<sup>+</sup> cDC1 cells are implicated in activating CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and the loss of the cDC1 population led to a decreased absolute count of CD8<sup>+</sup> T cells in the lymph nodes of HFD treated mice. Whereas in mice treated with a ND, the loss of the cDC1 population resulted in reduced frequencies of activated memory T cells but did not affect the absolute counts of T cells. Attenuated T cell activation might account for the mitigated atherosclerosis in Xcr1<sup>+</sup> cDC1 depleted mice.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4.</label>
<caption><title>Specific depletion of Xcr1<sup>+</sup> cDC1 cells in ApoE<sup>−/−</sup> mice decreases T cell activation within aorta.</title>
<p><bold>A</bold>, Representative flow cytometric analysis cDC1 cells in aortas. <bold>B</bold> and <bold>C</bold>, Quantification of the frequencies and absolute counts of cDC1 cells in aorta (n = 4). <bold>D</bold>, Representative flow cytometric analysis T cells in aortas. <bold>E</bold> and <bold>F</bold>, Quantification of the frequencies and absolute counts of total T, CD4<sup>+</sup> and CD8<sup>+</sup> T cells in aortas. <bold>G</bold>, Quantification of the frequencies of CD4<sup>+</sup>CD69<sup>+</sup> and CD8<sup>+</sup> CD69<sup>+</sup> in aortas. <bold>H</bold>, Quantification of the MFI of CD44 in CD4<sup>+</sup> and CD8<sup>+</sup> T cells in aortas. <bold>(</bold>D-G, ApoE<sup>−/−</sup> mice, n = 8, Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice, n = 7, fed on a HFD for 16 weeks). Data represent as mean ± SEM. * <italic>P</italic>&lt;0.05, ** <italic>P</italic>&lt;0.01, *** <italic>P</italic>&lt;0.001, NS, non-significant.</p></caption>
<graphic xlink:href="655779v3_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2e">
<title>Characterization of aortic Xcr1<sup>+</sup> cDC1 cells in atherosclerotic lesions</title>
<p>Although the majority of cDC1 cells derive from bone marrow, other mechanisms such as local proliferation of existing DCs can also contribute to the cDC1 population in inflammatory diseases [<xref ref-type="bibr" rid="c39">39</xref>, <xref ref-type="bibr" rid="c40">40</xref>]. It remains unclear whether cDC1 cells in lymphoid organs such as spleen and lymph nodes represent a different status compared to cDC1 cells in atherosclerotic lesions. To elucidate the source and status of Xcr1<sup>+</sup> cDC1 in atherosclerotic lesions, we performed bone marrow transplantation and single-cell RNA sequencing (sc-RNA seq) of cDC1 cells from aortic plaques and lymphoid organs. We conducted bone marrow transplantation using Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> or WT mice that carry the CD45.2 congenic markers as donors, and CD45.1<sup>+</sup> CD45.2<sup>+</sup> ApoE<sup>−/−</sup> mice as recipients (<xref ref-type="fig" rid="figS7">Figure S7A</xref>). Our data showed that body weight, lipid profile, and hepatic lipid accumulation were comparable between two groups of bone marrow transplanted mice after being fed with a HFD for 16 weeks (<xref ref-type="fig" rid="figS7">Figure S7B-D</xref>). Interestingly, flow cytometric analysis of the aorta displayed almost complete depletion of cDC1 cells in ApoE<sup>−/−</sup> recipient mice transplanted with Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> bone marrow mice (<xref ref-type="fig" rid="figS7">Figure S7E</xref>). Strikingly we did not find observe significant changes in pDCs and CD64<sup>+</sup>F4/80<sup>+</sup> aortic macrophages (<xref ref-type="fig" rid="figS7">Figure S7E-F</xref>). Therefore, our bone marrow transplantation experiments further confirmed fidelity of the Cre recombinase expression in cDC1 cells in mice.</p>
<p>Next, we carried out sc-RNA seq to characterize Xcr1<sup>+</sup> cDC1 cells from multiple organs of hyperlipidemic mice. Due to the scarcity of Xcr1<sup>+</sup> cDC1 cells that can be sorted by FACS and processed for sc-RNA seq, we pooled FACS sorted Xcr1<sup>+</sup> cDC1 cells from three organs of hyperlipidemic ApoE-deficient mice fed a HFD for 20 weeks, including the aorta, spleen, and lymph nodes, and Xcr1<sup>+</sup> cDC1 cells from aorta and splenocytes of ApoE-deficient mice fed a ND. Libraries for sc-RNA seq were prepared using barcode oligos conjugated to anti-CD45 antibodies for surface staining so that samples from each type of organ could be compared in sequential analyses. Therefore, we had a total of five samples, and our focus was to understand the differences between Xcr1<sup>+</sup> cDC1 cells from three different organs under hyperlipidemic conditions. The cells were sorted by gating Xcr1-positive cells out of the MHCII<sup>+</sup>CD11c<sup>+</sup> conventional dendritic cells (<xref ref-type="fig" rid="figS8">Figure S8</xref>). Firstly, we obtained the UMAP plot of 10 clusters of cDC1 cells using the Seurat 4.0 package (<xref rid="fig5" ref-type="fig">Figure 5A</xref>). In this analysis, 3830 quality-controlled Xcr1<sup>+</sup> cDC1 cells were from three types of organs in hyperlipidemic mice, and an additional 2081 cells were from cDC1 cells sorted from the spleen and aorta of ApoE deficient mice fed on a ND. The clusters were differentiated according to top 10 differentially expressed genes (<xref ref-type="table" rid="tblS1">Supplementary Table 1</xref>), and the heatmap shows marker genes and heterogeneity among the 10 clusters of cDC1 cells (<xref rid="fig5" ref-type="fig">Figure 5B</xref>). The purpose of this experiment was to determine whether cDC1 cells from different organs possess unique features and whether cDC1 cells from aortic lesions can be characterized by the expression of marker genes. In hyperlipidemic mice, cDC1 cells from the spleen and lymph nodes differed quite dramatically in Cluster 2 (<italic>Stk17b</italic> and <italic>Gpr171</italic> highly expressing cells), where 28.9% of cDC1 cells from the spleen versus 1.0% of cDC1 cells from the lymph nodes were located. Conversely, 3.15% of cDC1 cells from the spleen versus 32.4% of cDC1 cells from the lymph nodes fell in Cluster 3 (<italic>Ccl5</italic> and <italic>Epsti1</italic> highly expressing cells), and 4.6% of cDC1 cells from the spleen versus 25.9% of cDC1 cells from the lymph nodes fell in Cluster 4 (<italic>Slfn5</italic> and <italic>Ifi44</italic> highly expressing cells). Despite the fact that we had only transcriptomic data for 68 Xcr1<sup>+</sup> cDC1 cells from aortic lesions, we were surprised to find that such aortic cDC1 mainly fell into Cluster 1, 4 and 5, comprising 80.8% of the cells analyzed (<xref rid="fig5" ref-type="fig">Figure 5C</xref>). In Cluster 1 (<italic>Hspa1b</italic> and <italic>Dnajb1</italic> highly expressing cells), where aortic cDC1 is dominantly enriched, the cDC1 cells sorted from lymph nodes were essentially absent, while in Cluster 4, aortic cDC1 cells were highly enriched and splenic cDC1 was obviously lower in percentage (<xref rid="fig5" ref-type="fig">Figure 5C</xref>). Cluster 7 (<italic>Fabp5</italic> and <italic>S100a4</italic> highly expressing cells) is exclusively comprised of cDC1 cells sourced from lymph nodes, with a striking absence of cDC1 cells from the spleen and aorta (<xref rid="fig5" ref-type="fig">Figure 5C</xref>). To better visualize the enrichment of aortic Xcr1<sup>+</sup> cDC1 cells distributed in a few clusters, we separately compared the three samples from the spleen, lymph nodes, and aorta of hyperlipidemic mice using density plots. Interestingly, the Xcr1<sup>+</sup> cDC1 cells from the spleen and lymph nodes displayed an obvious difference in their distribution, and aortic Xcr1<sup>+</sup> cDC1 cells appeared more enriched in a few clusters (<xref rid="fig5" ref-type="fig">Figure 5D-E</xref>). Therefore, our data suggest that Xcr1<sup>+</sup> cDC1 cells from the spleen and lymph nodes can differ markedly in heterogeneity, and aortic Xcr1<sup>+</sup> cDC1 cells are enriched in a few clusters that express marker genes, <italic>Ccr2</italic>, <italic>Sept3</italic> and <italic>Cldnd1</italic> (<xref ref-type="table" rid="tblS2">Supplementary Table 2</xref>). Using the scRNA seq data of Xcr1<sup>+</sup> cDC1 sorted from hyperlipidemic mice, we annotated the 10 populations as shown in <xref ref-type="fig" rid="figS9">Figure S9A</xref>, following the methodology from a previous study [<xref ref-type="bibr" rid="c41">41</xref>]. <italic>Ccr7<sup>+</sup></italic> mature cDC1s (Cluster 3, 7 and 9) and <italic>Ccr7-</italic>immature cDC1s (remaining clusters) were identified across cDC1 cells sorted from aorta, spleen and lymph nodes (<xref ref-type="fig" rid="figS9">Figure S9B</xref>). Further stratification based on marker genes reveals that Cluster 10 is the pre-cDC1, with high expression level of <italic>CD62L (Sell)</italic> and low expression level of <italic>CD8a</italic> (<xref ref-type="fig" rid="figS9">Figure S9C</xref>). Cluster 6 and 8 are the proliferating cDC1s, which express high level of cell cycling genes <italic>Stmn1</italic> and <italic>Top2a</italic> (<xref ref-type="fig" rid="figS9">Figure S9D</xref>). Cluster 1 and 4 are early immature cDC1s, and cluster 2 and 5 are late immature cDC1s, according to the expression pattern of <italic>Itgae</italic>, <italic>Nr4a2</italic> (<xref ref-type="fig" rid="figS9">Figure S9E</xref>). Cluster 9 cells are early mature cDC1s, with elevated expression of <italic>Cxcl9</italic> and <italic>Cxcl10</italic> (<xref ref-type="fig" rid="figS9">Figure S9F</xref>). Cluster 3 and 7 as late mature cDC1s, characterized by the expression of <italic>Cd63</italic> and <italic>Fscn1</italic> (<xref ref-type="fig" rid="figS9">Figure S9G</xref>). As shown in <xref rid="fig5" ref-type="fig">Figure 5C</xref> and <xref ref-type="fig" rid="figS9">Figure S9</xref>, the 10 populations displayed a major difference of aortic cDC1 cells that lack in pre-cDC1s (cluster 10) and mature cells (cluster 3, 7 and 9). Interestingly, in hyperlipidemic mice splenic cDC1 possess only Cluster 3 as the late mature cells while the lymph node cDC1 cells have two late mature populations namely Cluster 3 and Cluster 7. In further analysis, we also compared splenic cDC1 cells from HFD mice to those from ND mice. As shown in <xref ref-type="fig" rid="figS10">Figure S10</xref>, HFD appears to impact early immature cDC1-1 cells (Cluster 1) and increases the abundance of late immature cDC1 cells (Cluster 2 and 5), regardless of the fact that all 10 populations are present in two origins of samples. We also found that <italic>Tnfaip3</italic> and <italic>Serinc3</italic> are among the most upregulated genes, while <italic>Apol7c</italic> and <italic>Tifab</italic> are downregulated in splenic cDC1 cells sorted from HFD mice.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5.</label>
<caption><title>Sc-RNA sequencing analysis of the aorta, lymph nodes and spleen in ApoE<sup>−/−</sup> mice fed with a 20-week HFD.</title>
<p><bold>A</bold>, UMAP plot delineates 10 annotated cell types of Xcr1<sup>+</sup> cDC1 cells from aorta, lymph node and spleen in ApoE<sup>−/−</sup> mice maintained on a HFD or ND for 20 weeks. <bold>B</bold>, Heatmap statistic map displays the top ten up-regulated genes across various clusters. <bold>C</bold>, The proportion of 10 clusters among groups. <bold>D</bold> and <bold>E</bold>, UMAP plot representing Xcr1<sup>+</sup> cDC1 cells from aorta, lymph nodes, spleen, and a merged plot in ApoE<sup>−/−</sup> mice maintained on a HFD for 20 weeks.</p></caption>
<graphic xlink:href="655779v3_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Together, these data implied that Xcr1<sup>+</sup> cDC1 in the aorta originate from bone marrow, and Xcr1<sup>+</sup> cDC1 cells exhibit strong heterogeneity among aorta, spleen and lymph nodes.</p>
</sec>
<sec id="s2f">
<title>Knockout of Xcl1 attenuates the development of atherosclerosis in ApoE<sup>−/−</sup> mice</title>
<p>Xcl1 is the major chemokine involved in cDC1 recruitment [<xref ref-type="bibr" rid="c42">42</xref>, <xref ref-type="bibr" rid="c43">43</xref>], and plays critical role in immune response with diverse physical and pathological implication through its interaction with the sole receptor, Xcr1 [<xref ref-type="bibr" rid="c44">44</xref>, <xref ref-type="bibr" rid="c45">45</xref>]. We found the presence of Xcl1 in the lesion area in both human and mouse atherosclerotic lesions (data not shown). To elucidate the causal relationship between Xcl1 and Xcr1<sup>+</sup> cDC1 in the development of atherosclerosis, and more importantly to experimentally verify Xcl1 as a potential therapeutic target for atherosclerosis treatment, we established the Xcl1 and ApoE double knockout mice. After being fed with a HFD for 19 weeks, both Xcl1<sup>−/−</sup> ApoE<sup>−/−</sup> and ApoE<sup>−/−</sup> mice were sacrificed to assess the severity of atherosclerosis. As shown in <xref rid="fig6" ref-type="fig">Figure 6A-D</xref>, the size of lesion at the descending aorta and aortic root was significantly smaller in Xcl1<sup>−/−</sup> ApoE<sup>−/−</sup> compared to that in ApoE<sup>−/−</sup> mice. Importantly, ORO staining of the liver, body weight and blood lipid profiles revealed no significant differences between the two groups (<xref rid="fig6" ref-type="fig">Figure 6E-H</xref>). Moreover, the IHC experiment result show the percentage of CD68 positive macrophages in aortic lesion was similar between two groups (<xref rid="fig6" ref-type="fig">Figure 6I-J</xref>).</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6.</label>
<caption><title>Xcl1 deficiency reduces atherosclerotic lesion formation in ApoE<sup>−/−</sup> mice.</title>
<p><bold>A</bold>, ORO staining of the descending aortas. Scale bar, 5 mm. <bold>B</bold>, Quantification of the lesion area in aortas. <bold>C</bold>, ORO and H&amp;E staining of aortic roots. Scale bar, 200 μm. <bold>D</bold>, Quantification of the lesion area in aortic roots. <bold>E</bold> and <bold>F</bold>, Representative liver images and quantification of ORO positive area in livers (n = 24 regions from 8 mice, 3 regions per mice). Scale bar, 100 μm. <bold>G</bold>, The concentrations of TC, TG, LDL and HDL in the serum. <bold>H</bold>, Body weight of mice before and after feeding with 19-week HFD. <bold>I</bold>, Representative immunohistochemical staining of CD68 in aortic roots. <bold>J</bold>, Quantification of CD68 positive area in the lesions of aortic roots (n = 24 lesions from 8 mice, 3 lesions per mice). Scale bar, 100 μm. ApoE<sup>−/−</sup> mice and Xcl1<sup>−/−</sup> ApoE<sup>−/−</sup> mice fed a HFD for 19 weeks (n = 8 per group). Data represent as mean ± SEM. ** <italic>P</italic>&lt;0.01, *** <italic>P</italic>&lt;0.001, NS, non-significant.</p></caption>
<graphic xlink:href="655779v3_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Previous study identified that Xcl1 serves as a potent chemokine, selectively acting on cDC1 cells through its exclusive receptor, Xcr1 [<xref ref-type="bibr" rid="c43">43</xref>]. Consequently, we examined the DCs and the activation of T cells in different organs, including aorta, lymph node and spleen. The flow cytometric results illustrated that both frequencies and absolute counts of Xcr1<sup>+</sup> cDC1 cells in the aorta were significantly reduced, but cDCs and cDC2 cells from Xcl1<sup>−/−</sup> ApoE<sup>−/−</sup> were comparable with that from ApoE<sup>−/−</sup> (<xref rid="fig7" ref-type="fig">Figure 7A-C</xref>). Moreover, in both lymph node and spleen, the absolute numbers of pDC, cDC1 and cDC2 from Xcl1<sup>−/−</sup> ApoE<sup>−/−</sup> were comparable with that from ApoE<sup>−/−</sup> (<xref ref-type="fig" rid="figS11">Figure S11</xref>). Crucially, CD69<sup>+</sup> frequency and CD44 MFI remained comparable in both aortic CD4<sup>+</sup> and CD8<sup>+</sup> T cells between two groups (<xref rid="fig7" ref-type="fig">Figure 7D-F</xref>). However, aortic CD8<sup>+</sup> T cells exhibited reduced frequency and absolute count, while CD4<sup>+</sup> T cells showed increased frequency but unchanged counts in Xcl1<sup>−/−</sup> ApoE<sup>−/−</sup> mouse versus controls (<xref rid="fig7" ref-type="fig">Figure 7G</xref> and <xref rid="fig7" ref-type="fig">H</xref>). Furthermore, the absolute numbers of CD4<sup>+</sup>, CD8<sup>+</sup>, CD4<sup>+</sup> CD69<sup>+</sup> and CD8<sup>+</sup> CD69<sup>+</sup> T cells in both lymph node and spleen from Xcl1<sup>−/−</sup> ApoE<sup>−/−</sup> mouse were comparable with that from ApoE<sup>−/−</sup> mouse (<xref ref-type="fig" rid="figS12">Figure S12</xref>).</p>
<fig id="fig7" position="float" orientation="portrait" fig-type="figure">
<label>Figure 7.</label>
<caption><title>Xcl1 deficiency reduces CD8<sup>+</sup> T cells in the aortas from ApoE<sup>−/−</sup> mice.</title>
<p><bold>A</bold>, Representative flow cytometric analysis of cDC, cDC1 and cDC2 cells in aortas. <bold>B</bold> and <bold>C</bold>, Quantification of the frequencies and absolute counts of cDC, cDC1 and cDC2 cells in aortas (n = 7). <bold>D</bold>, Representative flow cytometric analysis of T cell subsets in aortas, including CD3e<sup>+</sup> CD5<sup>+</sup>, CD4<sup>+</sup>, CD4<sup>+</sup> CD69<sup>+</sup>, CD8<sup>+</sup> and CD8<sup>+</sup> CD69<sup>+</sup> T cells. <bold>E</bold>, Quantification of the frequencies of CD4<sup>+</sup>CD69<sup>+</sup> and CD8<sup>+</sup> CD69<sup>+</sup> in aortas. <bold>F</bold>, Quantification of the MFI of CD44 in CD4<sup>+</sup> and CD8<sup>+</sup> T cells in aortas. <bold>G</bold> and <bold>H</bold>, Quantification of the frequencies and absolute counts of CD3e<sup>+</sup> CD5<sup>+</sup>, CD4<sup>+</sup> and CD8<sup>+</sup> cells in aortas. (D-H, ApoE<sup>−/−</sup> mice (n = 5) and Xcl1<sup>−/−</sup>ApoE<sup>−/−</sup> mice (n = 6) fed with a 16-week HFD). Data represent as mean ± SEM. * <italic>P</italic>&lt;0.05, NS, non-significant.</p></caption>
<graphic xlink:href="655779v3_fig7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Collectively, these data suggest that Xcl1 promotes atherosclerosis by recruiting Xcr1<sup>+</sup> cDC1 cells, and facilitating CD8<sup>+</sup> T cell accumulation in lesions. More importantly, <italic>in vivo</italic> data demonstrated the promising potential of targeting Xcl1 to reduce the inflammatory response in atherosclerotic lesions. Our work paves the way to discover novel solutions for the treatment of atherosclerosis by targeting Xcl1 and Xcr1<sup>+</sup> cDC1 cells.</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Atherosclerosis is a complex disorder, and understanding the role of the immune system, particularly dendritic cells (DCs), is of paramount importance [<xref ref-type="bibr" rid="c46">46</xref>, <xref ref-type="bibr" rid="c47">47</xref>]. The marked diversity of DC subsets and their distinct, and at times contradictory functions pose challenges in clarifying the role of each specific type of DC in the context of atherosclerosis [<xref ref-type="bibr" rid="c48">48</xref>–<xref ref-type="bibr" rid="c54">54</xref>]. Moreover, the restricted characterization of each subset of DCs in atherosclerosis, especially when compared to that in well-studied organs such as the skin and lymph nodes [<xref ref-type="bibr" rid="c13">13</xref>], has been severely hindered by the limited application of appropriate genetic models and <italic>in vivo</italic> data. Equally significant is that dissecting the functions of each subset of DCs <italic>in vivo</italic> relies on the development of genetic tools validated for lineage specificity. Recently, Xcr1<sup>+</sup> cDC1 has been extensively investigated using the Cre line under the promoter of the Xcr1, despite well-documented expression leakiness [<xref ref-type="bibr" rid="c20">20</xref>, <xref ref-type="bibr" rid="c31">31</xref>]. Compelling evidence from tumor and viral infection models [<xref ref-type="bibr" rid="c14">14</xref>, <xref ref-type="bibr" rid="c42">42</xref>, <xref ref-type="bibr" rid="c55">55</xref>–<xref ref-type="bibr" rid="c57">57</xref>], as well as metabolic disorders like non-alcoholic steatohepatitis [<xref ref-type="bibr" rid="c58">58</xref>], has demonstrated the critical role of Xcr1<sup>+</sup> cDC1 cells in diseases. Nevertheless, the precise role of Xcr1<sup>+</sup> cDC1 cells in atherosclerosis remains undetermined.</p>
<p>The precise characterization of Xcr1<sup>+</sup> cDC1 and its functions within the atherosclerotic milieu could provide valuable insights into the immunopathogenesis of the disease. By delineating the specific contributions of Xcr1<sup>+</sup> cDC1, we may identify novel therapeutic targets and develop more targeted and effective strategies for the prevention and treatment of atherosclerosis. Therefore, investigation to understand the roles of Xcr1<sup>+</sup> cDC1 in the context of atherosclerosis and to identify therapeutic targets is highly warranted. However, at least two major obstacles impede the <italic>in vivo</italic> study of Xcr1<sup>+</sup> cDC1 in atherosclerotic mice. First, Xcr1<sup>+</sup> cDC1 cells are extremely scarce in number, and it is quite challenging to obtain highly purified Xcr1<sup>+</sup> cDC1 cells from aortic plaque in hyperlipidemic mice. Second, there are very few appropriate genetic model systems that permit functional analyses of Xcr1<sup>+</sup> cDC1 <italic>in vivo</italic>. Earlier studies on the role of Xcr1<sup>+</sup> cDC1 cells in atherosclerosis have yielded conflicting results, largely due to the use of different mouse models. For instance, the deletion of Batf3, Irf8, Dngr1, or Flt3 decreased the cDC1 cells. Nevertheless, Batf3 deficiency had no impact on atherosclerosis in hyperlipidemic mice. In contrast, Irf8 or Dngr1 deficiency reduced the development of atherosclerosis, while Flt3 deficiency exacerbated the condition [<xref ref-type="bibr" rid="c15">15</xref>–<xref ref-type="bibr" rid="c19">19</xref>]. The recently developed Xcr1-Cre was found to have leakiness of recombinase activity in other immune cells [<xref ref-type="bibr" rid="c20">20</xref>]. Here, we optimized the design for the construction of the Cre line using the endogenous promoter of Xcr1 and validated its fidelity under hyperlipidemic conditions. We crossed the novel knock-in line termed Xcr1<sup>Cre-Gfp</sup> with Rosa26<sup>LSL-tdRFP</sup> Cre reporter mice and used the resulting F1 hybrids as bone marrow donors. The bone marrow cells were then transferred into ApoE<sup>−/−</sup> mice, which were subsequently fed on a HFD. We monitored the Cre recombinase activity, which was reflected by the tdRFP expression of this novel mouse line. Under hyperlipidemic conditions, we did not observe any leakiness of Cre activity, as tdRFP was strictly restricted to cDC1 cells. To the best of our knowledge, this novel Cre line is the first of its kind. We further crossed the Xcr1<sup>Cre-Gfp</sup> and Rosa26<sup>LSL-DTA</sup> mice with ApoE<sup>−/−</sup> mice respectively. Subsequently, by further crossing, we obtained Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice to create a complex genetic model, in which Xcr1<sup>+</sup> cDC1 is depleted <italic>in vivo</italic> in the context of atherosclerosis. Very interestingly, in the Xcr1<sup>+</sup> cDC1 depleted mice, atherosclerosis was significantly ameliorated. Coupled with the data we obtained from murine and human samples, where Xcr1<sup>+</sup> cDC1 cells exist in the aortic plaque and their accumulation is correlated with disease progression, we conclude that Xcr1<sup>+</sup> cDC1 is essential for the development of atherosclerosis.</p>
<p>Despite the fact that Xcr1<sup>+</sup> cDC1 cells are extremely rare in number, we were inclined to understand if there were any differences among Xcr1<sup>+</sup> cDC1 cells from different organs. Firstly, we determined that the Xcr1<sup>+</sup> cDC1 in the aortic plaque is replenished by circulating precursors using the bone marrow transfer model. Then we compared, under hyperlipidemic conditions, the Xcr1<sup>+</sup> cDC1 cells sorted from the spleen and lymph nodes, supplemented by a small number of but well-purified Xcr1<sup>+</sup> cDC1 cells from aortic lesions. To our surprise, the clusters of Xcr1<sup>+</sup> cDC1 displayed obvious distinctions among different organs. When the Xcr1<sup>+</sup> cDC1 cells from aortic lesions were projected to the clusters, we found that the major subsets present in the lymph nodes, characterized by the expression of markers <italic>Ccl5 and Fabp5</italic>, and in the spleen, marked by <italic>Stk17b</italic> and <italic>Gpr171</italic>, were basically absent in the aorta. Meanwhile, compared with spleen and lymph nodes, the aortic Xcr1<sup>+</sup> cDC1 cells are highly expressed <italic>Ccr2</italic>, which is an extremely important chemokine receptor dominating monocyte homing [<xref ref-type="bibr" rid="c59">59</xref>–<xref ref-type="bibr" rid="c61">61</xref>].</p>
<p>This pronounced tissue-specific compartmentalization of Xcr1⁺ cDC1 subsets may related to multiple mechanisms including developmental imprinting that instructs precursor differentiation into transcriptionally distinct subpopulations [<xref ref-type="bibr" rid="c62">62</xref>], and microenvironmental filtering through organ-specific chemokine axes (e.g., CCL2/CCR2 in spleen) selectively recruits receptor-matched subsets [<xref ref-type="bibr" rid="c63">63</xref>, <xref ref-type="bibr" rid="c64">64</xref>]. This spatial specialization optimizes pathogen surveillance for local immunological challenges. Based on the maturation analysis of the cDC1 scRNA seq data [<xref ref-type="bibr" rid="c41">41</xref>], our findings suggest that the aortic cDC1 cells display a major difference from those of spleen and lymph nodes by lacking the mature clusters, whereas lymph node cDC1 cells contain an additional <italic>Fabp5<sup>+</sup> S100a4<sup>+</sup></italic> late mature Cluster. Our results also suggest that hyperlipidemia contributes to alteration in early immature cDC1 and in the abundance of late immature cDC1 cells, which was associated with dramatic change in gene expression of <italic>Tnfaip3</italic>, <italic>Serinc3</italic>, <italic>Apol7c</italic> and <italic>Tifab</italic>.</p>
<p>In other disease models, Xcr1<sup>+</sup> cDC1 cells are crucial for activating T cells [<xref ref-type="bibr" rid="c56">56</xref>, <xref ref-type="bibr" rid="c65">65</xref>], and we confirmed that in hyperlipidemic mice, the depletion of cDC1 substantially attenuated T cell activation responses. It is important to note that Xcr1<sup>+</sup> cDC1 cells are known for well-established role in cross-presentation to CD8<sup>+</sup> T cells, recent studies have shown Xcr1<sup>+</sup> cDC1 cells also engage with CD4<sup>+</sup> T cells [<xref ref-type="bibr" rid="c20">20</xref>, <xref ref-type="bibr" rid="c27">27</xref>]. Our data showing Xcr1<sup>+</sup> cDC1-dependent CD4 and CD8 T cell activation in atherosclerotic plaques is in line with the new paradigm for cDC1s as a platform for both CD4 and CD8 T cell responses in the novel context of atherosclerosis. Considering the multifaceted roles of macrophages in lipid metabolism, inflammation, and plaque dynamics during the development of atherosclerosis [<xref ref-type="bibr" rid="c66">66</xref>], we evaluated the presence of macrophages in atherosclerotic lesions using IHC and flow cytometry. Our results indicated comparable proportions of macrophages in the aorta between Xcr1<sup>+</sup> cDC1 depleted mice and ApoE<sup>−/−</sup> control mice. Additionally, our results also demonstrated that the loss of Xcr1<sup>+</sup> cDC1 cells did not affect lipid status.</p>
<p>Since we elucidated the critical role of Xcr1<sup>+</sup> cDC1 cells in atherosclerosis, our aim was to test the therapeutic potential of inhibiting this specific cell type during disease progression. As Xcr1 is the sole receptor for Xcl1, and Xcl1 selectively attracts Xcr1<sup>+</sup> cDC1 cells in both mice and humans [<xref ref-type="bibr" rid="c45">45</xref>, <xref ref-type="bibr" rid="c67">67</xref>], we performed Xcl1 knockout on the background of ApoE deficient mice and assessed the impact on atherosclerosis development. We found that the Xcl1-Xcr1 axis plays a crucial role in the progression of atherosclerosis. Our results demonstrated that the loss of Xcl1 in hyperlipidemic ApoE<sup>−/−</sup> mice significantly reduced atherosclerotic lesion formation, decreased the frequencies and absolute coutns of Xcr1<sup>+</sup> cDC1 cells and CD8<sup>+</sup> T cells in the aorta, without affecting lipid status or the number of aortic macrophages. Notably, while complete ablation of Xcr1<sup>+</sup> cDC1s impaired T cell activation, reduction of Xcr1<sup>+</sup> cDC1 recruitment via Xcl1 deletion did not significantly compromise this process. This discrepancy may arise through compensatory mechanisms: alternative chemokine axes (e.g., CCL5/CCR5, CXCL9/CXCR3, BCL9/BCL9L) may partially rescue Xcr1<sup>+</sup> cDC1 homing [<xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c68">68</xref>, <xref ref-type="bibr" rid="c69">69</xref>], while non-cDC1 antigen-presenting cells (e.g., monocytes, cDC2s) may sustain T cell activation [<xref ref-type="bibr" rid="c55">55</xref>, <xref ref-type="bibr" rid="c70">70</xref>]. Furthermore, tissue-specific microenvironment factors could potentially modulate its role in other diseases. In summary, our findings identify Xcl1 as a potential therapeutic target for atherosclerosis therapy, though its cellular origins and regulation of lesional Xcr1<sup>+</sup> cDC1 and T cells dynamics require further studies.</p>
</sec>
<sec id="s4">
<title>Materials and Methods</title>
<sec id="s4a">
<title>Animal experiments and patients</title>
<p>All mice were raised in a Specific Pathogen-Free facility and the experiments were conducted in accordance with the guidelines approved by the Animal Ethics Committee of Xinxiang Medical University (China) (Reference No. XYLL-2016S001). The sections of the human femoral artery were obtained in accordance with our previous study [<xref ref-type="bibr" rid="c30">30</xref>] and approved by the Ethics Committee of the Third Military Medical University (Project identification code SYXK-PLA-20170005). Rosa26<sup>LSL-RFP</sup> knock-in mice were generously provided by Hervé Luche at University Clinics Ulm in Germany [<xref ref-type="bibr" rid="c32">32</xref>]. C57BL/6 and ApoE<sup>−/−</sup> mice were purchased from Beijing Vital River Laboratory Animal Technology (China). Rosa26<sup>LSL-DTA</sup> knock-in mice (Stock Number 009669) were purchased from the Jackson Laboratory (United States of America). Both HFD (contained 20% protein, 20% carbohydrate, 40% fat and 1.25% cholesterol, Cat: XT108C), and ND (contained 20% protein, 64% carbohydrate, 20% fat, Cat: AIN-93G) were purchased from Jiangsu Xietong Pharmaceutical Bioengineering Co., Ltd. 7-8 weeks old mice were used to establish atherosclerosis model through fed on a HFD for 8-20 weeks. On harvest, each sample was assigned an analytical code that was irrelevant to its genotype and processed and analyzed by a researcher blinded to its origin.</p>
</sec>
<sec id="s4b">
<title>Generation of Xcr1<sup>Cre-Gfp</sup> knock-in mice</title>
<p>The Xcr1<sup>Cre-Gfp</sup> mouse line was generated by inserting a Cre-P2A-GFP-P2A cassette immediately upstream of the endogenous <italic>Xcr1</italic> translational start codon (ATG). This design enables co-expression of Cre recombinase and GFP under the control of the native <italic>Xcr1</italic> promoter. A 3.2-kb repair template was synthesized (GenScript, Nanjing, China), consisting of a 0.62-kb 5’ homology arm (HA), a codon-optimized <italic>Cre</italic> sequence fused to a P2A peptide, an enhanced GFP reporter linked to a second P2A site, and a 0.67-kb 3’ homology arm. For targeted integration, CRISPR/Cas9-mediated homology-directed repair (HDR) was performed by co-injecting Cas9 mRNA, a chimeric sgRNA (sgXcr1-KI), and the repair template into fertilized C57BL/6 zygotes at the one-cell stage, following established protocols[<xref ref-type="bibr" rid="c71">71</xref>, <xref ref-type="bibr" rid="c72">72</xref>]. Founders (F0) harboring the correct knock-in allele were identified by PCR and Sanger sequencing, then used to establish heterozygous lines. The sgRNA sequence is provided in <xref ref-type="table" rid="tblS3">Supplementary Table 3</xref>.</p>
</sec>
<sec id="s4c">
<title>Breeding strategy of Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup></title>
<p>To generate Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice, we performed the following crosses: Xcr1<sup>Cre-Gfp</sup> mice were crossed with ApoE<sup>−/−</sup> mice, and offspring heterozygous for both alleles were intercrossed to obtain homozygous Xcr1<sup>Cre-Gfp</sup> ApoE<sup>−/−</sup> mice. Rosa26<sup>LSL-DTA</sup> mice were crossed with ApoE<sup>−/−</sup> mice, and progeny heterozygous for both alleles were intercrossed to generate homozygous Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice. Finally, homozygous Xcr1<sup>Cre-Gfp</sup> ApoE<sup>−/−</sup> mice were crossed with homozygous Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice to produce Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> offspring.</p>
</sec>
<sec id="s4d">
<title>Generation of Xcl1 knockout mice</title>
<p>The Xcl1 knockout mouse line was generated using CRISPR/Cas9 genome editing through the microinjection of a mixture containing Cas9 mRNA and two sgRNAs into fertilized C57BL/6 zygotes at the one-cell stage, as previously described [<xref ref-type="bibr" rid="c73">73</xref>]. The genotypes were confirmed using PCR and Sanger sequencing. Subsequently, Xcl1 and ApoE double knockout mice were obtained by crossing the Xcl1<sup>−/−</sup> mice with ApoE<sup>−/−</sup> mice. The sequences of the sgRNA are reported in <xref ref-type="table" rid="tblS3">Supplementary Table 3</xref>.</p>
</sec>
<sec id="s4e">
<title>Bone marrow transplantation</title>
<p>After one week of antibiotic treatment, the recipient CD45.1<sup>+</sup> CD45.2<sup>+</sup> ApoE<sup>−/−</sup> mice were injected intraperitoneally with busulfan at a dosage of 30 μg/g every two days for one week. Subsequently, bone marrow from 8-week-old CD45.2<sup>+</sup> Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-RFP</sup>, CD45.2<sup>+</sup> Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> or WT (CD45.2<sup>+</sup> wild-type) donor mice was intravenously transferred to each recipient mouse, with two million cells administered per recipient. The efficiency of transplantation was assessed four-week post-transplantation, after which all mice were fed a HFD for 16 weeks. Finally, the mice were sacrificed for <italic>en face</italic> analysis of the descending aorta, hematoxylin and eosin (H&amp;E) staining, Oil Red O (ORO) staining of the aortic root, and flow cytometry analysis, as previously described [<xref ref-type="bibr" rid="c74">74</xref>].</p>
</sec>
<sec id="s4f">
<title>Immunofluorescence</title>
<p>Frozen sections of the aortic root from mice were incubated at 60 °C for 2 minutes and then fixed in 4% paraformaldehyde for 30 minutes. The samples were subsequently washed with PBS and permeabilized/blocked with 0.1% Triton X-100 in 5% BSA. Next, the primary antibodies, including anti-Xcr1 (BD Biosciences, Cat. 148212) and anti-CD11c (BD Biosciences, Cat. 12-0114-83), were applied in a wet box at 4 °C overnight. After washing with PBST (PBS containing 0.1% Tween-20) for five times, the samples were incubated with secondary antibodies for 1 hour, followed by a 10-minute incubation with DAPI at room temperature (protected from light). The fluorescent signals of the sections were detected using a Nikon C2 confocal microscope (Nikon, Japan).</p>
</sec>
<sec id="s4g">
<title>Morphometric and immunohistochemical analyses</title>
<p>After modeling, the heart and aorta tissue were obtained from mice. The <italic>en face</italic> descending aortas were fixed with 4% paraformaldehyde and subsequently stained with ORO. Additionally, frozen sections of the aortic roots were stained with ORO and H&amp;E to assess the severity of atherosclerosis, and frozen sections of livers were stained with ORO to assess the severity of lipid accumulation, in accordance with our previous study [<xref ref-type="bibr" rid="c74">74</xref>]. Paraffin-embedded sections of the aortic root were dewaxed in xylene twice for 10 minutes, rehydrated through descending grades of ethanol, and subjected to sodium citrate-induced antigen retrieval for 10 minutes at 95 °C. The sections were then incubated with 3% H₂O₂ for 10 minutes at room temperature. Following this, the sections were blocked and incubated with primary antibodies, either anti-Xcr1 (NBP1-02343) or CD68 (FB113109). After five washes with DPBS, the sections were incubated with secondary antibodies for 30 minutes and stained with DAB at room temperature. Subsequently, the sections were counterstained with hematoxylin, dehydrated in ethanol, and mounted with neutral balsam. Images were captured using the digital pathology system (Pannoramic MIDI, Hungary), viewed using CaseViewer2.4 software and analyzed using ImageJ software.</p>
</sec>
<sec id="s4h">
<title>Flow cytometry analysis</title>
<p>To obtain the single-cell suspension, aortas, lymph nodes and spleens were collected from each mouse. Spleens were directly dissociated using the Gentle MACS Dissociators (Miltenyi Biotec). Aortas and lymph nodes were cut into small pieces and then dissociated using the Gentle MACS Dissociators. Dissociated tissues digested with digestive enzymes (Collagenase IV, Cat: V900893 from Sigma; DNase I, Cat: DN25 from Sigma; Liberase DH, Cat: 5401054001 from Roche) for 30 minutes at 37 °C using a shaker set to 300 rpm or a heating block. The resulting cell suspension was filtered through 75 µm strainers and subsequently blocked with 2.4G2 for 20 minutes at 4 °C, followed by washing with stain buffer (BD, Cat: 554656). Then samples were stained with monoclonal antibody mixes for 30 minutes at 4 °C followed by washing with stain buffer. Finally, cells were resuspended in stain buffer containing 200 nM Sytox blue (ThermoFisher Scientific, Cat: S34857) and acquired using a flow cytometer (ThermoFisher Scientific, Invitrogen Attune NxT Flow Cytometer), and the FACS data were analyzed using FlowJo software. The following antibodies purchased from BioLegend, BD or eBioscience were used to detect surface markers by flow cytometry: anti-CD45.2 (104) conjugated to eFluor 450, FITC or PE-Cy7; anti-CD45.1 (A20) conjugated to PE or eFluor450; anti-CD45 (30-F11) conjugated to PE; anti-CD11b (M1/70) conjugated to super Bright 600, BUV395 or biotin; anti-CD3e (145-2C11) conjugated to PE-Cy5.5 or PE-Cy7; anti-CD3e (eBio500A2) conjugated to Alexa Fluor700; anti-CD19 (eBio1D3) conjugated to PE-Cy5.5 or biotin; anti-Xcr1 (ZET) conjugated to APC or BV650; anti-Ly6G (1A8) conjugated to Alexa Fluor 700; anti-MHCII (M5/114.15.2) conjugated to APC-eFluor780; anti-CD11c (N418) conjugated to PE or PE-Cy5.5; anti-Siglec H (eBio440c) conjugated to PE-Cy7 or PE; anti-CD8b (eBioH35-17.2) conjugated to eFluor 450; anti-CD44 (IM7) conjugated to BV605; anti-CD4 (RM4-5) conjugated to PE-Cy5.5; anti-CD69 (H1.2F3) conjugated to PE-Cy7; anti-CD62L (MEL-14) conjugated to APC; anti-CD5 (53-7.3) conjugated to APC-eFluor780 or biotin; anti-Siglec F (E50-2440) conjugated to BV421; anti-F4/80 (BM8) conjugated to PE-Cy7; anti-CD64 (X54-5/7.1) conjugated to APC; anti-NK1.1 (PK136) conjugated to Alexa Fluor 700; anti-CD172α (P84) conjugated to FITC.</p>
</sec>
<sec id="s4i">
<title>Single cell RNA sequencing</title>
<p>Eight-week-old male ApoE<sup>−/−</sup> mice were fed with 20-week ND or HFD. The single cell suspension of spleen, lymph node and aorta were obtained according to the flow cytometry analysis section. Single cell suspension from spleens and lymph nodes were firstly removed the CD5<sup>+</sup>, CD19<sup>+</sup> and CD11b<sup>+</sup> cells via SAV conjugated beads. Then two million live cells from spleen and lymph node were stained with mix1 (CD45.2-PE-Cy7, CD11c-PE-Cy5.5, CD172α-FITC, MHCII-APC-eFluor780 and Xcr1-APC), and all cells from aorta were stained with mix2 (CD45.2-PE-Cy7, CD11b-super bright 600, CD11c-PE-Cy5.5, MHCII-FITC, CD3-Alexa Fluor 700, CD19-Alexa Fluor 700, Ly6G-Alexa Fluor 700 and Xcr1-APC) for 30 minutes at 4 °C. After washing with 1 mL FACS buffer two times, cells from different organs were stained with different anti-CD45 antibodies conjugated with barcode oligos from BD™ Ms Single Cell Sample Multiplexing Kit (BD Bioscience, Cat: 633793). Finally, cells were resuspended with Sytox blue and CD11c<sup>+</sup> MHCII<sup>+</sup> Xcr1<sup>+</sup> cells were sorted and subjected to the BD Rhapsody Express system. Then cDNA and sample tag libraries were built with BD Rhapsody whole transcriptome amplification (WTA) reagent kit (BD Bioscience, Cat: 633733, 633773, 633801, 664887) following manufacturer’s instructions, and sequenced on an illumine Novaseq 600 sequencer. Pair-end Fastq files of sample tag and WTA data were processed via BD Rhapsody<sup>TM</sup> analysis pipeline v2.0, and the resultant dataset was mainly analysis using SeqGeq<sup>TM</sup> software, which contain Lex-BDSMK and Seurat v4.04 plugin components. Raw data and processed data were uploaded into GEO (Accession number: GSE279370).</p>
</sec>
<sec id="s4j">
<title>Statistical analysis</title>
<p>All data were presented as means ± SEM (Standard Error of the Mean), reflecting the average values of biological measurements across multiple samples. Data analysis was performed using GraphPad Prism software (version 8.0). Statistical significance was assessed by both parametric (unpaired Student’s <italic>t</italic>-test) and nonparametric (Mann–Whitney test) methods when comparing two groups. The assumptions of the tests were checked to ensure appropriate application. Significant differences between different groups were set at * <italic>P&lt;</italic>0.05, ** <italic>P&lt;</italic>0.01, *** <italic>P&lt;</italic>0.001 and **** <italic>P&lt;</italic>0.0001. Graphical representations of the data will include bar graphs with error bars denoting SEM.</p>
</sec>
</sec>
</body>
<back>
<sec>
<fig id="figS1" position="float" orientation="portrait" fig-type="figure">
<label>Figure S1.</label>
<caption><title>Schematic diagram illustrating the knock-in of the 5’HA-iCre-P2A-EGFP-P2A-3’HA vector into the mouse Xcr1 locus.</title></caption>
<graphic xlink:href="655779v3_figS1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS2" position="float" orientation="portrait" fig-type="figure">
<label>Figure S2.</label>
<caption><title>Flow cytometric analysis of cDC1 cells in the lymph nodes and spleens of ApoE<sup>−/−</sup> mice and Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice fed a 7-weeks ND.</title>
<p><bold>A</bold>, Representative flow cytometric analysis of cDC1 cells in lymph nodes. <bold>B</bold>, Quantification of the frequencies and number of cDC1 cell in lymph nodes. <bold>C</bold>, Representative flow cytometric analysis cDC1 cells in the spleens. <bold>D</bold>, Quantification of the frequencies and number of cDC1 cell in the spleens. ApoE<sup>−/−</sup> mice and Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice fed with 7-week ND, n = 7. Data represent the mean ± SEM. *** <italic>P</italic>&lt;0.001.</p></caption>
<graphic xlink:href="655779v3_figS2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS3" position="float" orientation="portrait" fig-type="figure">
<label>Figure S3.</label>
<caption><title>Lipid profile, body weight and ORO staining of the liver in ApoE<sup>−/−</sup> mice and Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice fed a 16-week HFD.</title>
<p><bold>A</bold>, Concentrations of TC, TG, LDL and HDL in the serum. <bold>B</bold>, Body weight measurements of both groups of mice. <bold>C</bold>, ORO staining of liver from each group. Scale bar, 100 μm. <bold>D</bold>, Quantification of ORO positive area in liver. ApoE<sup>−/−</sup> mice (n =7) and Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice (n =8) were fed on a 16-week HFD to develop atherosclerosis. Data represent the mean ± SEM. NS, non-significant.</p></caption>
<graphic xlink:href="655779v3_figS3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS4" position="float" orientation="portrait" fig-type="figure">
<label>Figure S4.</label>
<caption><title>Flow cytometric analysis of cDC1 cells in the lymph nodes and spleens of ApoE<sup>−/−</sup> and Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice fed a 16-week HFD.</title>
<p><bold>A</bold>, Representative flow cytometric analysis of cDC1 cells in lymph nodes. <bold>B</bold>, Quantification of the frequencies and numbers of cDC1 cells in lymph nodes. <bold>C</bold>, Representative flow cytometric analysis of cDC1 cells in the spleens. <bold>D</bold>, Quantification of the frequencies and numbers of cDC1 cells in the spleens. ApoE<sup>−/−</sup> mice (n =7) and Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice (n =8) were fed on a 16-week HFD. Data represent the mean ± SEM. *** <italic>P</italic>&lt;0.001.</p></caption>
<graphic xlink:href="655779v3_figS4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS5" position="float" orientation="portrait" fig-type="figure">
<label>Figure S5.</label>
<caption><title>Flow cytometric analysis of T cells in the lymph nodes and spleens of ApoE<sup>−/−</sup> mice and Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice fed a 16-week HFD.</title>
<p><bold>A</bold>, Representative flow cytometric analysis of CD4<sup>+</sup>, CD8<sup>+</sup>, CD4<sup>+</sup>CD69<sup>+</sup> and CD8<sup>+</sup>CD69<sup>+</sup> T cells in lymph nodes. <bold>B</bold> and <bold>C</bold>, Quantification of the frequencies and numbers of CD4<sup>+</sup>, CD8<sup>+</sup>, CD4<sup>+</sup> CD69<sup>+</sup> and CD8<sup>+</sup> CD69<sup>+</sup> T cells in lymph nodes. <bold>D</bold>, Representative flow cytometric analysis and quantification of CD4<sup>+</sup>, CD8<sup>+</sup>, CD4<sup>+</sup> CD69<sup>+</sup> and CD8<sup>+</sup> CD69<sup>+</sup> T cells in the spleens. <bold>E</bold> and <bold>F</bold>, Quantification of the frequencies and numbers of CD4<sup>+</sup>, CD8<sup>+</sup>, CD4<sup>+</sup> CD69<sup>+</sup> and CD8<sup>+</sup>CD69<sup>+</sup> T cells in the spleens. ApoE<sup>−/−</sup> mice (n =7) and Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice (n =8) were fed on a 16-week HFD. Data represent the mean ± SEM. * <italic>P</italic>&lt;0.05, ** <italic>P</italic>&lt;0.01, *** <italic>P</italic>&lt;0.001, NS, non-significant.</p></caption>
<graphic xlink:href="655779v3_figS5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS6" position="float" orientation="portrait" fig-type="figure">
<label>Figure S6.</label>
<caption><title>T cells analysis in the lymph nodes and spleens of ApoE<sup>−/−</sup> mice and Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice fed a 7-week ND.</title>
<p><bold>A</bold>, Representative flow cytometric analysis and quantification of CD4<sup>+</sup>, CD4<sup>+</sup> memory, CD8<sup>+</sup> and CD8<sup>+</sup> memory T cells in lymph nodes. <bold>B</bold>, Quantification of the frequencies of CD4<sup>+</sup>, CD8<sup>+</sup>, CD4<sup>+</sup>CD69<sup>+</sup> and CD8<sup>+</sup>CD69<sup>+</sup> T cells in the lymph nodes. <bold>C</bold>, Representative flow cytometric analysis and quantification of CD4<sup>+</sup>, CD4<sup>+</sup> memory, CD8<sup>+</sup> and CD8<sup>+</sup> memory T cells in the spleens. <bold>D</bold>, Quantification of the frequencies of CD4<sup>+</sup>, CD8<sup>+</sup>, CD4<sup>+</sup> CD69<sup>+</sup> and CD8<sup>+</sup> CD69<sup>+</sup> T cells in the spleens. <bold>E</bold> and <bold>F</bold>, Quantification of the numbers of CD4<sup>+</sup> and CD8<sup>+</sup> T cells in the lymph nodes and spleens. ApoE<sup>−/−</sup> mice and Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>−/−</sup> mice fed with a 7-week ND (n = 6). Data represent the mean ± SEM. * <italic>P</italic>&lt;0.05, ** <italic>P</italic>&lt;0.01, NS, non-significant.</p></caption>
<graphic xlink:href="655779v3_figS6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS7" position="float" orientation="portrait" fig-type="figure">
<label>Figure S7.</label>
<caption><title>Depletion of Xcr1<sup>+</sup> cDC1 cells of bone marrow reduces cDC1 cells without affecting macrophages in atherosclerotic lesion of ApoE<sup>−/−</sup> mice.</title>
<p><bold>A</bold>, Diagram of the bone marrow transfer process. ApoE<sup>−/−</sup> mice transplanted with bone marrow from WT or Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> donors (n = 7). <bold>B</bold>, Body weight of each group. <bold>C</bold>, Serum concentrations of TC, TG, LDL and HDL. <bold>D</bold>, Representative ORO staining images of liver sections and quantification of the ORO positive area percentage in the liver. Scale bar, 50 μm. <bold>E</bold>, Representative flow cytometric analysis of pDC, cDC1 and cDC2 cells in the aortas, Lin<sup>-</sup> means CD3<sup>-</sup> CD19<sup>-</sup> Ly6G<sup>-</sup> NK1.1<sup>-</sup>. <bold>F</bold>, Flow cytometric analysis of macrophages in the aortas. Data represent as mean ± SEM. *** <italic>P</italic>&lt;0.001, NS, non-significant.</p></caption>
<graphic xlink:href="655779v3_figS7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS8" position="float" orientation="portrait" fig-type="figure">
<label>Figure S8.</label>
<caption><title>The single-cell RNA sequencing process.</title></caption>
<graphic xlink:href="655779v3_figS8.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS9" position="float" orientation="portrait" fig-type="figure">
<label>Figure S9.</label>
<caption><title>Sc-RNA sequencing analysis of the aorta, lymph nodes and spleen in ApoE<sup>−/−</sup> mice.</title>
<p><bold>A</bold>, UMAP plot delineates 10 annotated cell types of Xcr1<sup>+</sup> cDC1 cells from aorta, lymph node and spleen in ApoE<sup>−/−</sup> mice maintained on a HFD or ND for 20 weeks. <bold>B</bold>-<bold>G</bold>, Heatmap statistic map showing marker genes in different clusters. <italic>Ccr7</italic> is the mature gene marker (B). <italic>Sell<sup>+</sup>CD8a<sup>-</sup></italic> cDC1s are defined as Pre-cDC1s (C). <italic>Stmn1</italic> and <italic>Top2a</italic> are the proliferating markers (D). <italic>Itgae</italic> and <italic>Nr4a2</italic> genes marked the transition from early to late immature cDC1s (E). <italic>Cxcl9</italic> and <italic>Cxcl10</italic> genes marked the transition from late immature to early mature cDC1s (F). <italic>Cd63</italic> and <italic>Fscn1</italic> are the late mature markers (G).</p></caption>
<graphic xlink:href="655779v3_figS9.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS10" position="float" orientation="portrait" fig-type="figure">
<label>Figure S10.</label>
<caption><title>Single-cell RNA sequencing of splenic cDC1s from both the HFD and ND groups.</title>
<p><bold>A</bold>, UMAP plot of splenic cDC1s showing annotated clusters. <bold>B</bold>, The proportions of cDC1 maturation states across diet groups. <bold>C</bold>-<bold>H</bold>, Heatmap statistic map depicting representative markers defining cDC1 maturation clusters. <italic>Ccr7</italic> is the mature gene marker (C). <italic>Sell<sup>+</sup>CD8a<sup>-</sup></italic> cDC1s are defined as Pre-cDC1s (D). <italic>Top2a</italic>, <italic>Stmn1</italic> and <italic>Mki67</italic> are the proliferating markers (E). <italic>Itgae</italic>, <italic>Nr4a2</italic>, <italic>Nr4a3</italic> and <italic>Egr3</italic> genes marked the transition from early to late immature cDC1s (F). <italic>Cxcl9</italic> and <italic>Cxcl10</italic> genes marked the transition from late immature to early mature cDC1s (G). <italic>Cd63</italic> and <italic>Fscn1</italic> are the late mature markers (H). <bold>I</bold>-<bold>J</bold>, Heatmap statistic map of upregulated genes (<italic>Tnfaip3</italic> and <italic>Serinc3</italic>), and downregulated genes (<italic>Apol7c</italic> and <italic>Tifab</italic>) in the HFD spleen compared to the ND spleen.</p></caption>
<graphic xlink:href="655779v3_figS10.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS11" position="float" orientation="portrait" fig-type="figure">
<label>Figure S11.</label>
<caption><title>DC cells analysis in lymph nodes and spleens of ApoE<sup>−/−</sup> and Xcl1<sup>−/−</sup> ApoE<sup>−/−</sup> mice fed with 19-week HFD.</title>
<p><bold>A</bold>, Representative flow cytometric analysis and quantification of pDC, cDCs, cDC1 and cDC2 cells in lymph nodes. <bold>B</bold>, Quantification of absolute counts of pDC, cDCs, cDC1 and cDC2 cells in lymph nodes. <bold>C</bold>, Representative flow cytometric analysis of pDC, cDC1 and cDC2 cells in spleens. <bold>D</bold>, Quantification of absolute counts of pDC, cDCs, cDC1 and cDC2 cells in spleens. ApoE<sup>−/−</sup> (n = 9) and Xcl1<sup>−/−</sup> ApoE<sup>−/−</sup> mice (n = 7 or 8) fed a HFD for 19 weeks. Data represent the mean ± SEM. NS, non-significant.</p></caption>
<graphic xlink:href="655779v3_figS11.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS12" position="float" orientation="portrait" fig-type="figure">
<label>Figure S12.</label>
<caption><title>T cells analysis in lymph node and spleen of ApoE<sup>−/−</sup> and Xcl1<sup>−/−</sup> ApoE<sup>−/−</sup> mice fed with 16-week HFD.</title>
<p><bold>A</bold> and <bold>B</bold>, Representative flow cytometric analysis and quantification of absolute counts of CD4<sup>+</sup>, CD8<sup>+</sup>, CD4<sup>+</sup>CD69<sup>+</sup> and CD8<sup>+</sup>CD69<sup>+</sup> T cells in lymph nodes (ApoE<sup>−/−</sup>, n = 9; Xcl1<sup>−/−</sup> ApoE<sup>−/−</sup>, n = 7). <bold>C</bold> and <bold>D</bold>, Representative flow cytometric analysis and quantification of absolute counts of CD4<sup>+</sup>, CD8<sup>+</sup>, CD4<sup>+</sup>CD69<sup>+</sup> and CD8<sup>+</sup>CD69<sup>+</sup> T cells in spleens (ApoE<sup>−/−</sup>, n = 10; Xcl1<sup>−/−</sup> ApoE<sup>−/−</sup>, n = 7). Data represent the mean ± SEM. NS, non-significant.</p></caption>
<graphic xlink:href="655779v3_figS12.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<table-wrap id="tblS1" orientation="portrait" position="float">
<label>Supplementary table 1:</label>
<caption><title>The top ten high-expressed marker genes in ten clusters</title></caption>
<graphic xlink:href="655779v3_tblS1a.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="655779v3_tblS1b.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="655779v3_tblS1c.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
<table-wrap id="tblS2" orientation="portrait" position="float">
<label>Supplementary table 2:</label>
<caption><title>Up regulated genes in Xcr1<sup>+</sup> cDC1 cells from aorta vs spleen, and aorta vs lymph node in ApoE-deficient mice fed a HFD for 20 weeks</title></caption>
<graphic xlink:href="655779v3_tblS2a.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="655779v3_tblS2b.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
<table-wrap id="tblS3" orientation="portrait" position="float">
<label>Supplementary table 3:</label>
<caption><title>The sequences of the sgRNA used for generation of Xcr1<sup>Cre-Gfp</sup> knock-in mice and Xcl1 knockout mice</title></caption>
<graphic xlink:href="655779v3_tblS3.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
</sec>
<ack>
<title>Acknowledgements</title>
<p>We thank the animal facility and flow cytometry facility of GRIS in Xinxiang Medical University for providing technical support and assistance. Generation of murine genetic models were supported by 111 program (D20036).</p>
</ack>
<sec id="d1e2622" sec-type="additional-information">
<title>Additional information</title>
<sec id="s5">
<title>Author Contributions</title>
<p><bold>Lichen Zhang</bold> and <bold>Yinming Liang</bold> conceived the project. <bold>Tianhan Li</bold> and <bold>Liaoxun Lu</bold> wrote the manuscript and carried out the majority of the experiments. <bold>Bernard Malissen</bold> and <bold>Lichen Zhang</bold> designed the Xcr1Cre-Gfp knock-in mice and Xcl1 knockout mice. <bold>Juanjuan Qiu</bold>, <bold>Xin Dong</bold>, <bold>Le Yang</bold>, <bold>Kexin He</bold>, and <bold>Yanrong Gu</bold> assisted in the experimental procedures. <bold>Binhui Zhou</bold> performed cell sorting for scRNA sequencing. <bold>Tingting Jia</bold> and <bold>Rong Huang</bold> contributed to data curation and validation. <bold>Toby Lawrence</bold>, <bold>Marie Malissen</bold>, and <bold>Hui Wang</bold> participated in the manuscript review and editing. <bold>Guixue Wang</bold> assisted in the preparation of human samples. <bold>Yinming Liang</bold>, <bold>Lichen Zhang</bold>, and <bold>Tianhan Li</bold> contributed to obtaining the funding for the project.</p>
</sec>
<sec id="s6">
<title>Funding</title>
<p>This research was funded by grants from Science and Technology Innovation Program of Hunan Province [2023DK2005], [2024RC1071] and [2022RC1223], and NSFC grants 32170879 and 82301972, and Science and Technology Department of Henan Province 242102310030.</p>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bjorkegren</surname> <given-names>JLM</given-names></string-name>, <string-name><surname>Lusis</surname> <given-names>AJ</given-names></string-name></person-group>. <article-title>Atherosclerosis: Recent developments</article-title>. <source>Cell</source>. <year>2022</year>;<volume>185</volume>(<issue>10</issue>):<fpage>1630</fpage>–<lpage>45</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2022.04.004</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">35504280</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC9119695</pub-id>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hansson</surname> <given-names>GK</given-names></string-name>, <string-name><surname>Hermansson</surname> <given-names>A</given-names></string-name></person-group>. <article-title>The immune system in atherosclerosis</article-title>. <source>Nat Immunol</source>. <year>2011</year>;<volume>12</volume>(<issue>3</issue>):<fpage>204</fpage>–<lpage>12</lpage>. Epub 2011/02/16. doi: <pub-id pub-id-type="doi">10.1038/ni.2001</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">21321594</pub-id>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lusta</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Poznyak</surname> <given-names>AV</given-names></string-name>, <string-name><surname>Sukhorukov</surname> <given-names>VN</given-names></string-name>, <string-name><surname>Eremin</surname>, <given-names>II</given-names></string-name>, <string-name><surname>Nadelyaeva</surname>, <given-names>II</given-names></string-name>, <string-name><surname>Orekhov</surname> <given-names>AN</given-names></string-name></person-group>. <article-title>Hypotheses on Atherogenesis Triggering: Does the Infectious Nature of Atherosclerosis Development Have a Substruction?</article-title> <source>Cells</source>. <year>2023</year>;<volume>12</volume>(<issue>5</issue>). doi: <pub-id pub-id-type="doi">10.3390/cells12050707</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">36899843</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC10001176</pub-id>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hansson</surname> <given-names>GK</given-names></string-name>, <string-name><surname>Robertson</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Soderberg-Naucler</surname> <given-names>C</given-names></string-name></person-group>. <article-title>Inflammation and atherosclerosis</article-title>. <source>Annu Rev Pathol</source>. <year>2006</year>;<volume>1</volume>:<fpage>297</fpage>–<lpage>329</lpage>. Epub 2007/11/28. doi: <pub-id pub-id-type="doi">10.1146/annurev.pathol.1.110304.100100</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">18039117</pub-id>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hasham</surname> <given-names>SN</given-names></string-name>, <string-name><surname>Pillarisetti</surname> <given-names>S</given-names></string-name></person-group>. <article-title>Vascular lipases, inflammation and atherosclerosis</article-title>. <source>Clin Chim Acta</source>. <year>2006</year>;<volume>372</volume>(<issue>1-2</issue>):<fpage>179</fpage>–<lpage>83</lpage>. Epub 2006/06/13. doi: <pub-id pub-id-type="doi">10.1016/j.cca.2006.04.020</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">16765928</pub-id>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Steinman</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Hawiger</surname> <given-names>D</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>K</given-names></string-name>, <string-name><surname>Bonifaz</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bonnyay</surname> <given-names>D</given-names></string-name>, <string-name><surname>Mahnke</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Dendritic cell function in vivo during the steady state: a role in peripheral tolerance</article-title>. <source>Ann N Y Acad Sci</source>. <year>2003</year>;<volume>987</volume>:<fpage>15</fpage>–<lpage>25</lpage>. Epub 2003/05/03. doi: <pub-id pub-id-type="doi">10.1111/j.1749-6632.2003.tb06029.x</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">12727620</pub-id>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma-Krupa</surname> <given-names>W</given-names></string-name>, <string-name><surname>Jeon</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Spoerl</surname> <given-names>S</given-names></string-name>, <string-name><surname>Tedder</surname> <given-names>TF</given-names></string-name>, <string-name><surname>Goronzy</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Weyand</surname> <given-names>CM</given-names></string-name></person-group>. <article-title>Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis</article-title>. <source>J Exp Med</source>. <year>2004</year>;<volume>199</volume>(<issue>2</issue>):<fpage>173</fpage>–<lpage>83</lpage>. Epub 2004/01/22. doi: <pub-id pub-id-type="doi">10.1084/jem.20030850</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">14734523</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC2211768</pub-id>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname> <given-names>P</given-names></string-name>, <string-name><surname>Yu</surname> <given-names>YR</given-names></string-name>, <string-name><surname>Spencer</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Vallanat</surname> <given-names>CT</given-names></string-name>, <string-name><surname>Fong</surname> <given-names>AM</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>CX3CR1 deficiency impairs dendritic cell accumulation in arterial intima and reduces atherosclerotic burden</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2008</year>;<volume>28</volume>(<issue>2</issue>):<fpage>243</fpage>–<lpage>50</lpage>. Epub 2007/12/15. doi: <pub-id pub-id-type="doi">10.1161/ATVBAHA.107.158675</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">18079406</pub-id>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jongstra-Bilen</surname> <given-names>J</given-names></string-name>, <string-name><surname>Haidari</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>SN</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Guha</surname> <given-names>D</given-names></string-name>, <string-name><surname>Cybulsky</surname> <given-names>MI</given-names></string-name></person-group>. <article-title>Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis</article-title>. <source>J Exp Med</source>. <year>2006</year>;<volume>203</volume>(<issue>9</issue>):<fpage>2073</fpage>–<lpage>83</lpage>. Epub 2006/08/09. doi: <pub-id pub-id-type="doi">10.1084/jem.20060245</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">16894012</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC2118407</pub-id>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bobryshev</surname> <given-names>YV</given-names></string-name>, <string-name><surname>Lord</surname> <given-names>RS</given-names></string-name></person-group>. <article-title>Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of Vascular Dendritic Cells in athero-resistant and athero-prone areas of the normal aorta</article-title>. <source>Arch Histol Cytol</source>. <year>1995</year>;<volume>58</volume>(<issue>3</issue>):<fpage>307</fpage>–<lpage>22</lpage>. Epub 1995/08/01. doi: <pub-id pub-id-type="doi">10.1679/aohc.58.307</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">8527238</pub-id>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kawahara</surname> <given-names>I</given-names></string-name>, <string-name><surname>Kitagawa</surname> <given-names>N</given-names></string-name>, <string-name><surname>Tsutsumi</surname> <given-names>K</given-names></string-name>, <string-name><surname>Nagata</surname> <given-names>I</given-names></string-name>, <string-name><surname>Hayashi</surname> <given-names>T</given-names></string-name>, <string-name><surname>Koji</surname> <given-names>T</given-names></string-name></person-group>. <article-title>The expression of vascular dendritic cells in human atherosclerotic carotid plaques</article-title>. <source>Hum Pathol</source>. <year>2007</year>;<volume>38</volume>(<issue>9</issue>):<fpage>1378</fpage>–<lpage>85</lpage>. Epub 2007/06/09. doi: <pub-id pub-id-type="doi">10.1016/j.humpath.2007.02.004</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">17555794</pub-id>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zernecke</surname> <given-names>A</given-names></string-name>, <string-name><surname>Erhard</surname> <given-names>F</given-names></string-name>, <string-name><surname>Weinberger</surname> <given-names>T</given-names></string-name>, <string-name><surname>Schulz</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ley</surname> <given-names>K</given-names></string-name>, <string-name><surname>Saliba</surname> <given-names>AE</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Integrated single-cell analysis based classification of vascular mononuclear phagocytes in mouse and human atherosclerosis</article-title>. <source>Cardiovasc Res</source>. <year>2022</year>. Epub 2022/10/04. doi: <pub-id pub-id-type="doi">10.1093/cvr/cvac161</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">36190844</pub-id>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eisenbarth</surname> <given-names>SC</given-names></string-name></person-group>. <article-title>Dendritic cell subsets in T cell programming: location dictates function</article-title>. <source>Nat Rev Immunol</source>. <year>2019</year>;<volume>19</volume>(<issue>2</issue>):<fpage>89</fpage>–<lpage>103</lpage>. Epub 2018/11/23. doi: <pub-id pub-id-type="doi">10.1038/s41577-018-0088-1</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">30464294</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC7755085</pub-id>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bayerl</surname> <given-names>F</given-names></string-name>, <string-name><surname>Meiser</surname> <given-names>P</given-names></string-name>, <string-name><surname>Donakonda</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hirschberger</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lacher</surname> <given-names>SB</given-names></string-name>, <string-name><surname>Pedde</surname> <given-names>AM</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses</article-title>. <source>Immunity</source>. <year>2023</year>;<volume>56</volume>(<issue>6</issue>):<fpage>1341</fpage>–<lpage>58 e11</lpage>. Epub 2023/06/15. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2023.05.011</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">37315536</pub-id>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Legein</surname> <given-names>B</given-names></string-name>, <string-name><surname>Janssen</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Theelen</surname> <given-names>TL</given-names></string-name>, <string-name><surname>Gijbels</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Walraven</surname> <given-names>J</given-names></string-name>, <string-name><surname>Klarquist</surname> <given-names>JS</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Ablation of CD8alpha(+) dendritic cell mediated cross-presentation does not impact atherosclerosis in hyperlipidemic mice</article-title>. <source>Scientific reports</source>. <year>2015</year>;<volume>5</volume>:<fpage>15414</fpage>. Epub 20151021. doi: <pub-id pub-id-type="doi">10.1038/srep15414</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">26486587</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC4614009</pub-id>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gil-Pulido</surname> <given-names>J</given-names></string-name>, <string-name><surname>Cochain</surname> <given-names>C</given-names></string-name>, <string-name><surname>Lippert</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Schneider</surname> <given-names>N</given-names></string-name>, <string-name><surname>Butt</surname> <given-names>E</given-names></string-name>, <string-name><surname>Amezaga</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Deletion of Batf3-dependent antigen-presenting cells does not affect atherosclerotic lesion formation in mice</article-title>. <source>PLoS One</source>. <year>2017</year>;<volume>12</volume>(<issue>8</issue>):<fpage>e0181947</fpage>. Epub 20170803. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0181947</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">28771609</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC5542449</pub-id>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Choi</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Cheong</surname> <given-names>C</given-names></string-name>, <string-name><surname>Dandamudi</surname> <given-names>DB</given-names></string-name>, <string-name><surname>Park</surname> <given-names>CG</given-names></string-name>, <string-name><surname>Rodriguez</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mehandru</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Flt3 signaling-dependent dendritic cells protect against atherosclerosis</article-title>. <source>Immunity</source>. <year>2011</year>;<volume>35</volume>(<issue>5</issue>):<fpage>819</fpage>–<lpage>31</lpage>. Epub 2011/11/15. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2011.09.014</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">22078798</pub-id>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clement</surname> <given-names>M</given-names></string-name>, <string-name><surname>Haddad</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Raffort</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lareyre</surname> <given-names>F</given-names></string-name>, <string-name><surname>Newland</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Master</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Deletion of IRF8 (Interferon Regulatory Factor 8)-Dependent Dendritic Cells Abrogates Proatherogenic Adaptive Immunity</article-title>. <source>Circ Res</source>. <year>2018</year>;<volume>122</volume>(<issue>6</issue>):<fpage>813</fpage>–<lpage>20</lpage>. Epub 2018/02/14. doi: <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.312713</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">29436389</pub-id>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haddad</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Lahoute</surname> <given-names>C</given-names></string-name>, <string-name><surname>Clement</surname> <given-names>M</given-names></string-name>, <string-name><surname>Laurans</surname> <given-names>L</given-names></string-name>, <string-name><surname>Metghalchi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zeboudj</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The Dendritic Cell Receptor DNGR-1 Promotes the Development of Atherosclerosis in Mice</article-title>. <source>Circ Res</source>. <year>2017</year>;<volume>121</volume>(<issue>3</issue>):<fpage>234</fpage>–<lpage>43</lpage>. Epub 2017/06/14. doi: <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.310960</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">28607102</pub-id>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wohn</surname> <given-names>C</given-names></string-name>, <string-name><surname>Le Guen</surname> <given-names>V</given-names></string-name>, <string-name><surname>Voluzan</surname> <given-names>O</given-names></string-name>, <string-name><surname>Fiore</surname> <given-names>F</given-names></string-name>, <string-name><surname>Henri</surname> <given-names>S</given-names></string-name>, <string-name><surname>Malissen</surname> <given-names>B</given-names></string-name></person-group>. <article-title>Absence of MHC class II on cDC1 dendritic cells triggers fatal autoimmunity to a cross-presented self-antigen</article-title>. <source>Sci Immunol</source>. <year>2020</year>;<volume>5</volume>(<issue>45</issue>). Epub 2020/03/15. doi: <pub-id pub-id-type="doi">10.1126/sciimmunol.aba1896</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">32169954</pub-id>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mundt</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mrdjen</surname> <given-names>D</given-names></string-name>, <string-name><surname>Utz</surname> <given-names>SG</given-names></string-name>, <string-name><surname>Greter</surname> <given-names>M</given-names></string-name>, <string-name><surname>Schreiner</surname> <given-names>B</given-names></string-name>, <string-name><surname>Becher</surname> <given-names>B</given-names></string-name></person-group>. <article-title>Conventional DCs sample and present myelin antigens in the healthy CNS and allow parenchymal T cell entry to initiate neuroinflammation</article-title>. <source>Sci Immunol</source>. <year>2019</year>;<volume>4</volume>(<issue>31</issue>). doi: <pub-id pub-id-type="doi">10.1126/sciimmunol.aau8380</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">30679199</pub-id>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robbins</surname> <given-names>CS</given-names></string-name>, <string-name><surname>Hilgendorf</surname> <given-names>I</given-names></string-name>, <string-name><surname>Weber</surname> <given-names>GF</given-names></string-name>, <string-name><surname>Theurl</surname> <given-names>I</given-names></string-name>, <string-name><surname>Iwamoto</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Figueiredo</surname> <given-names>JL</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Local proliferation dominates lesional macrophage accumulation in atherosclerosis</article-title>. <source>Nat Med</source>. <year>2013</year>;<volume>19</volume>(<issue>9</issue>):<fpage>1166</fpage>–<lpage>72</lpage>. Epub 2013/08/13. doi: <pub-id pub-id-type="doi">10.1038/nm.3258</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">23933982</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC3769444</pub-id>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Potteaux</surname> <given-names>S</given-names></string-name>, <string-name><surname>Gautier</surname> <given-names>EL</given-names></string-name>, <string-name><surname>Hutchison</surname> <given-names>SB</given-names></string-name>, <string-name><surname>van Rooijen</surname> <given-names>N</given-names></string-name>, <string-name><surname>Rader</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Thomas</surname> <given-names>MJ</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression</article-title>. <source>J Clin Invest</source>. <year>2011</year>;<volume>121</volume>(<issue>5</issue>):<fpage>2025</fpage>–<lpage>36</lpage>. Epub 2011/04/21. doi: <pub-id pub-id-type="doi">10.1172/JCI43802</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">21505265</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC3083793</pub-id>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yilmaz</surname> <given-names>A</given-names></string-name>, <string-name><surname>Weber</surname> <given-names>J</given-names></string-name>, <string-name><surname>Cicha</surname> <given-names>I</given-names></string-name>, <string-name><surname>Stumpf</surname> <given-names>C</given-names></string-name>, <string-name><surname>Klein</surname> <given-names>M</given-names></string-name>, <string-name><surname>Raithel</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Decrease in circulating myeloid dendritic cell precursors in coronary artery disease</article-title>. <source>J Am Coll Cardiol</source>. <year>2006</year>;<volume>48</volume>(<issue>1</issue>):<fpage>70</fpage>–<lpage>80</lpage>. Epub 2006/07/04. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2006.01.078</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">16814651</pub-id>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alberts-Grill</surname> <given-names>N</given-names></string-name>, <string-name><surname>Denning</surname> <given-names>TL</given-names></string-name>, <string-name><surname>Rezvan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Jo</surname> <given-names>H</given-names></string-name></person-group>. <article-title>The role of the vascular dendritic cell network in atherosclerosis</article-title>. <source>Am J Physiol Cell Physiol</source>. <year>2013</year>;<volume>305</volume>(<issue>1</issue>):<fpage>C1</fpage>–<lpage>21</lpage>. Epub 2013/04/05. doi: <pub-id pub-id-type="doi">10.1152/ajpcell.00017.2013</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">23552284</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC3725520</pub-id>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yan</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Thakur</surname> <given-names>M</given-names></string-name>, <string-name><surname>van der Vorst</surname> <given-names>EPC</given-names></string-name>, <string-name><surname>Weber</surname> <given-names>C</given-names></string-name>, <string-name><surname>Doring</surname> <given-names>Y</given-names></string-name></person-group>. <article-title>Targeting the chemokine network in atherosclerosis</article-title>. <source>Atherosclerosis</source>. <year>2021</year>;<volume>330</volume>:<fpage>95</fpage>–<lpage>106</lpage>. Epub 2021/07/13. doi: <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2021.06.912</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">34247863</pub-id>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eickhoff</surname> <given-names>S</given-names></string-name>, <string-name><surname>Brewitz</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gerner</surname> <given-names>MY</given-names></string-name>, <string-name><surname>Klauschen</surname> <given-names>F</given-names></string-name>, <string-name><surname>Komander</surname> <given-names>K</given-names></string-name>, <string-name><surname>Hemmi</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Robust Anti-viral Immunity Requires Multiple Distinct T Cell-Dendritic Cell Interactions</article-title>. <source>Cell</source>. <year>2015</year>;<volume>162</volume>(<issue>6</issue>):<fpage>1322</fpage>–<lpage>37</lpage>. Epub 2015/08/25. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2015.08.004</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">26296422</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC4567961</pub-id>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weber</surname> <given-names>C</given-names></string-name>, <string-name><surname>Zernecke</surname> <given-names>A</given-names></string-name>, <string-name><surname>Libby</surname> <given-names>P</given-names></string-name></person-group>. <article-title>The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models</article-title>. <source>Nat Rev Immunol</source>. <year>2008</year>;<volume>8</volume>(<issue>10</issue>):<fpage>802</fpage>–<lpage>15</lpage>. Epub 2008/10/01. doi: <pub-id pub-id-type="doi">10.1038/nri2415</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">18825131</pub-id>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Worbs</surname> <given-names>T</given-names></string-name>, <string-name><surname>Hammerschmidt</surname> <given-names>SI</given-names></string-name>, <string-name><surname>Forster</surname> <given-names>R</given-names></string-name></person-group>. <article-title>Dendritic cell migration in health and disease</article-title>. <source>Nat Rev Immunol</source>. <year>2017</year>;<volume>17</volume>(<issue>1</issue>):<fpage>30</fpage>–<lpage>48</lpage>. Epub 2016/11/29. doi: <pub-id pub-id-type="doi">10.1038/nri.2016.116</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">27890914</pub-id>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname> <given-names>T</given-names></string-name>, <string-name><surname>Safitri</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>K</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Downregulation of G3BP2 reduces atherosclerotic lesions in ApoE(-/-) mice</article-title>. <source>Atherosclerosis</source>. <year>2020</year>;<volume>310</volume>:<fpage>64</fpage>–<lpage>74</lpage>. Epub 2020/09/13. doi: <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2020.08.003</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">32919187</pub-id>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mattiuz</surname> <given-names>R</given-names></string-name>, <string-name><surname>Wohn</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ghilas</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ambrosini</surname> <given-names>M</given-names></string-name>, <string-name><surname>Alexandre</surname> <given-names>YO</given-names></string-name>, <string-name><surname>Sanchez</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Novel Cre-Expressing Mouse Strains Permitting to Selectively Track and Edit Type 1 Conventional Dendritic Cells Facilitate Disentangling Their Complexity in vivo</article-title>. <source>Front Immunol</source>. <year>2018</year>;<volume>9</volume>:<fpage>2805</fpage>. Epub 2018/12/20. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2018.02805</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">30564233</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC6288293</pub-id>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luche</surname> <given-names>H</given-names></string-name>, <string-name><surname>Weber</surname> <given-names>O</given-names></string-name>, <string-name><surname>Nageswara Rao</surname> <given-names>T</given-names></string-name>, <string-name><surname>Blum</surname> <given-names>C</given-names></string-name>, <string-name><surname>Fehling</surname> <given-names>HJ</given-names></string-name></person-group>. <article-title>Faithful activation of an extra-bright red fluorescent protein in “knock-in” Cre-reporter mice ideally suited for lineage tracing studies</article-title>. <source>European journal of immunology</source>. <year>2007</year>;<volume>37</volume>(<issue>1</issue>):<fpage>43</fpage>–<lpage>53</lpage>. Epub 2006/12/16. doi: <pub-id pub-id-type="doi">10.1002/eji.200636745</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">17171761</pub-id>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Meyer</surname> <given-names>GRY</given-names></string-name>, <string-name><surname>Zurek</surname> <given-names>M</given-names></string-name>, <string-name><surname>Puylaert</surname> <given-names>P</given-names></string-name>, <string-name><surname>Martinet</surname> <given-names>W</given-names></string-name></person-group>. <article-title>Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets</article-title>. <source>Nat Rev Cardiol</source>. <year>2024</year>. Epub 2024/01/02. doi: <pub-id pub-id-type="doi">10.1038/s41569-023-00957-0</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">38163815</pub-id>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname> <given-names>EPK</given-names></string-name>, <string-name><surname>Reinhold</surname> <given-names>J</given-names></string-name>, <string-name><surname>Yu</surname> <given-names>H</given-names></string-name>, <string-name><surname>Starks</surname> <given-names>L</given-names></string-name>, <string-name><surname>Uryga</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Foote</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Mitochondrial Respiration Is Reduced in Atherosclerosis, Promoting Necrotic Core Formation and Reducing Relative Fibrous Cap Thickness</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2017</year>;<volume>37</volume>(<issue>12</issue>):<fpage>2322</fpage>–<lpage>32</lpage>. Epub 2017/10/04. doi: <pub-id pub-id-type="doi">10.1161/ATVBAHA.117.310042</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">28970293</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC5701734</pub-id>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Piedrahita</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Hagaman</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Oliver</surname> <given-names>PM</given-names></string-name>, <string-name><surname>Maeda</surname> <given-names>N</given-names></string-name></person-group>. <article-title>Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1992</year>;<volume>89</volume>(<issue>10</issue>):<fpage>4471</fpage>–<lpage>5</lpage>. Epub 1992/05/15. doi: <pub-id pub-id-type="doi">10.1073/pnas.89.10.4471</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">1584779</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC49104</pub-id>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Plump</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Hayek</surname> <given-names>T</given-names></string-name>, <string-name><surname>Aalto-Setala</surname> <given-names>K</given-names></string-name>, <string-name><surname>Walsh</surname> <given-names>A</given-names></string-name>, <string-name><surname>Verstuyft</surname> <given-names>JG</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells</article-title>. <source>Cell</source>. <year>1992</year>;<volume>71</volume>(<issue>2</issue>):<fpage>343</fpage>–<lpage>53</lpage>. Epub 1992/10/16. doi: <pub-id pub-id-type="doi">10.1016/0092-8674(92)90362-g</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">1423598</pub-id>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fernandez</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Rahman</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Fernandez</surname> <given-names>NF</given-names></string-name>, <string-name><surname>Chudnovskiy</surname> <given-names>A</given-names></string-name>, <string-name><surname>Amir</surname> <given-names>ED</given-names></string-name>, <string-name><surname>Amadori</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Single-cell immune landscape of human atherosclerotic plaques</article-title>. <source>Nat Med</source>. <year>2019</year>;<volume>25</volume>(<issue>10</issue>):<fpage>1576</fpage>–<lpage>88</lpage>. Epub 2019/10/09. doi: <pub-id pub-id-type="doi">10.1038/s41591-019-0590-4</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">31591603</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC7318784</pub-id>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Afek</surname> <given-names>A</given-names></string-name>, <string-name><surname>Harats</surname> <given-names>D</given-names></string-name>, <string-name><surname>Roth</surname> <given-names>A</given-names></string-name>, <string-name><surname>Keren</surname> <given-names>G</given-names></string-name>, <string-name><surname>George</surname> <given-names>J</given-names></string-name></person-group>. <article-title>Evidence for the involvement of T cell costimulation through the B-7/CD28 pathway in atherosclerotic plaques from apolipoprotein E knockout mice</article-title>. <source>Exp Mol Pathol</source>. <year>2004</year>;<volume>76</volume>(<issue>3</issue>):<fpage>219</fpage>–<lpage>23</lpage>. Epub 2004/05/06. doi: <pub-id pub-id-type="doi">10.1016/j.yexmp.2003.12.001</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">15126104</pub-id>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cancel</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Crozat</surname> <given-names>K</given-names></string-name>, <string-name><surname>Dalod</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mattiuz</surname> <given-names>R</given-names></string-name></person-group>. <article-title>Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?</article-title> <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>9</fpage>. Epub 2019/02/28. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2019.00009</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">30809220</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC6379659</pub-id>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname> <given-names>N</given-names></string-name>, <string-name><surname>Steiger</surname> <given-names>S</given-names></string-name>, <string-name><surname>Fei</surname> <given-names>L</given-names></string-name>, <string-name><surname>Li</surname> <given-names>C</given-names></string-name>, <string-name><surname>Shi</surname> <given-names>C</given-names></string-name>, <string-name><surname>Salei</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>IRF8-Dependent Type I Conventional Dendritic Cells (cDC1s) Control Post-Ischemic Inflammation and Mildly Protect Against Post-Ischemic Acute Kidney Injury and Disease</article-title>. <source>Front Immunol</source>. <year>2021</year>;<volume>12</volume>:<fpage>685559</fpage>. Epub 2021/07/09. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.685559</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">34234783</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC8255684</pub-id>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bosteels</surname> <given-names>V</given-names></string-name>, <string-name><surname>Marechal</surname> <given-names>S</given-names></string-name>, <string-name><surname>De Nolf</surname> <given-names>C</given-names></string-name>, <string-name><surname>Rennen</surname> <given-names>S</given-names></string-name>, <string-name><surname>Maelfait</surname> <given-names>J</given-names></string-name>, <string-name><surname>Tavernier</surname> <given-names>SJ</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>LXR signaling controls homeostatic dendritic cell maturation</article-title>. <source>Sci Immunol</source>. <year>2023</year>;<volume>8</volume>(<issue>83</issue>):<fpage>eadd3955</fpage>. Epub 2023/05/12. doi: <pub-id pub-id-type="doi">10.1126/sciimmunol.add3955</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">37172103</pub-id>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bottcher</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Bonavita</surname> <given-names>E</given-names></string-name>, <string-name><surname>Chakravarty</surname> <given-names>P</given-names></string-name>, <string-name><surname>Blees</surname> <given-names>H</given-names></string-name>, <string-name><surname>Cabeza-Cabrerizo</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sammicheli</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control</article-title>. <source>Cell</source>. <year>2018</year>;<volume>172</volume>(<issue>5</issue>):<fpage>1022</fpage>–<lpage>37 e14</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2018.01.004</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">29429633</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC5847168</pub-id>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dorner</surname> <given-names>BG</given-names></string-name>, <string-name><surname>Dorner</surname> <given-names>MB</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>X</given-names></string-name>, <string-name><surname>Opitz</surname> <given-names>C</given-names></string-name>, <string-name><surname>Mora</surname> <given-names>A</given-names></string-name>, <string-name><surname>Guttler</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells</article-title>. <source>Immunity</source>. <year>2009</year>;<volume>31</volume>(<issue>5</issue>):<fpage>823</fpage>–<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2009.08.027</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">19913446</pub-id>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname> <given-names>F</given-names></string-name>, <string-name><surname>He</surname> <given-names>D</given-names></string-name>, <string-name><surname>Ning</surname> <given-names>R</given-names></string-name>, <string-name><surname>Zeng</surname> <given-names>B</given-names></string-name>, <string-name><surname>Thompson</surname> <given-names>CW</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Genetic diversity of chemokine XCL1 and its receptor XCR1 in murine rodents</article-title>. <source>Developmental and comparative immunology</source>. <year>2019</year>;<volume>98</volume>:<fpage>80</fpage>–<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.dci.2019.04.008</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">31026469</pub-id>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yoshida</surname> <given-names>T</given-names></string-name>, <string-name><surname>Izawa</surname> <given-names>D</given-names></string-name>, <string-name><surname>Nakayama</surname> <given-names>T</given-names></string-name>, <string-name><surname>Nakahara</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kakizaki</surname> <given-names>M</given-names></string-name>, <string-name><surname>Imai</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Molecular cloning of mXCR1, the murine SCM-1/lymphotactin receptor</article-title>. <source>FEBS letters</source>. <year>1999</year>;<volume>458</volume>(<issue>1</issue>):<fpage>37</fpage>–<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0014-5793(99)01114-x</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">10518929</pub-id>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tall</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Bornfeldt</surname> <given-names>KE.</given-names></string-name></person-group> <article-title>Inflammasomes and Atherosclerosis: a Mixed Picture</article-title>. <source>Circ Res</source>. <year>2023</year>;<volume>S32</volume>(<issue>11</issue>):<fpage>1505</fpage>–<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.123.321637</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">37228237</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC10213995</pub-id>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vallejo</surname> <given-names>J</given-names></string-name>, <string-name><surname>Cochain</surname> <given-names>C</given-names></string-name>, <string-name><surname>Zernecke</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ley</surname> <given-names>K</given-names></string-name></person-group>. <article-title>Heterogeneity of immune cells in human atherosclerosis revealed by scRNA-Seq</article-title>. <source>Cardiovasc Res</source>. <year>2021</year>;<volume>117</volume>(<issue>13</issue>):<fpage>2537</fpage>–<lpage>43</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cvr/cvab260</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">34343272</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC8921647</pub-id>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guo</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>T</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Lai</surname> <given-names>W</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>L</given-names></string-name></person-group>. <article-title>Generation of mouse and human dendritic cells in vitro</article-title>. <source>J Immunol Methods</source>. <year>2016</year>;<volume>432</volume>:<fpage>24</fpage>–<lpage>9</lpage>. Epub 2016/02/16. doi: <pub-id pub-id-type="doi">10.1016/j.jim.2016.02.011</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">26876301</pub-id>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anselmi</surname> <given-names>G</given-names></string-name>, <string-name><surname>Helft</surname> <given-names>J</given-names></string-name>, <string-name><surname>Guermonprez</surname> <given-names>P</given-names></string-name></person-group>. <article-title>Development and function of human dendritic cells in humanized mice models</article-title>. <source>Mol Immunol</source>. <year>2020</year>;<volume>125</volume>:<fpage>151</fpage>–<lpage>61</lpage>. Epub 2020/07/21. doi: <pub-id pub-id-type="doi">10.1016/j.molimm.2020.07.005</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">32688117</pub-id>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blanco</surname> <given-names>P</given-names></string-name>, <string-name><surname>Palucka</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Pascual</surname> <given-names>V</given-names></string-name>, <string-name><surname>Banchereau</surname> <given-names>J</given-names></string-name></person-group>. <article-title>Dendritic cells and cytokines in human inflammatory and autoimmune diseases</article-title>. <source>Cytokine Growth Factor Rev</source>. <year>2008</year>;<volume>19</volume>(<issue>1</issue>):<fpage>41</fpage>–<lpage>52</lpage>. Epub 2008/02/09. doi: <pub-id pub-id-type="doi">10.1016/j.cytogfr.2007.10.004</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">18258476</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC2413068</pub-id>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Steinman</surname> <given-names>RM</given-names></string-name></person-group>. <article-title>Dendritic cells: understanding immunogenicity</article-title>. <source>European journal of immunology</source>. <year>2007</year>;<volume>37</volume> <issue>Suppl 1</issue>:<fpage>S53</fpage>–<lpage>60</lpage>. Epub 2007/11/01. doi: <pub-id pub-id-type="doi">10.1002/eji.200737400</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">17972346</pub-id>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Steinman</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Adams</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Cohn</surname> <given-names>ZA</given-names></string-name></person-group>. <article-title>Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen</article-title>. <source>J Exp Med</source>. <year>1975</year>;<volume>141</volume>(<issue>4</issue>):<fpage>804</fpage>–<lpage>20</lpage>. Epub 1975/04/01. PubMed PMID: <pub-id pub-id-type="pmid">1127378</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC2189754</pub-id>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Steinman</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Kaplan</surname> <given-names>G</given-names></string-name>, <string-name><surname>Witmer</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Cohn</surname> <given-names>ZA</given-names></string-name></person-group>. <article-title>Identification of a novel cell type in peripheral lymphoid organs of mice. V. Purification of spleen dendritic cells, new surface markers, and maintenance in vitro</article-title>. <source>J Exp Med</source>. <year>1979</year>;<volume>149</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>16</lpage>. Epub 1979/01/01. doi: <pub-id pub-id-type="doi">10.1084/jem.149.1.1</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">762493</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC2184752</pub-id>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clark</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Silveira</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Hogarth</surname> <given-names>PM</given-names></string-name>, <string-name><surname>Hart</surname> <given-names>DNJ</given-names></string-name></person-group>. <article-title>The cell surface phenotype of human dendritic cells</article-title>. <source>Semin Cell Dev Biol</source>. <year>2019</year>;<volume>86</volume>:<fpage>3</fpage>–<lpage>14</lpage>. Epub 2018/03/03. doi: <pub-id pub-id-type="doi">10.1016/j.semcdb.2018.02.013</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">29499385</pub-id>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brewitz</surname> <given-names>A</given-names></string-name>, <string-name><surname>Eickhoff</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dahling</surname> <given-names>S</given-names></string-name>, <string-name><surname>Quast</surname> <given-names>T</given-names></string-name>, <string-name><surname>Bedoui</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kroczek</surname> <given-names>RA</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>CD8(+) T Cells Orchestrate pDC-XCR1(+) Dendritic Cell Spatial and Functional Cooperativity to Optimize Priming</article-title>. <source>Immunity</source>. <year>2017</year>;<volume>46</volume>(<issue>2</issue>):<fpage>205</fpage>–<lpage>19</lpage>. Epub 2017/02/14. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2017.01.003</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">28190711</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC5362251</pub-id>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alexandre</surname> <given-names>YO</given-names></string-name>, <string-name><surname>Ghilas</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sanchez</surname> <given-names>C</given-names></string-name>, <string-name><surname>Le Bon</surname> <given-names>A</given-names></string-name>, <string-name><surname>Crozat</surname> <given-names>K</given-names></string-name>, <string-name><surname>Dalod</surname> <given-names>M</given-names></string-name></person-group>. <article-title>XCR1+ dendritic cells promote memory CD8+ T cell recall upon secondary infections with Listeria monocytogenes or certain viruses</article-title>. <source>J Exp Med</source>. <year>2016</year>;<volume>213</volume>(<issue>1</issue>):<fpage>75</fpage>–<lpage>92</lpage>. Epub 2015/12/24. doi: <pub-id pub-id-type="doi">10.1084/jem.20142350</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">26694969</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC4710197</pub-id>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Domenjo-Vila</surname> <given-names>E</given-names></string-name>, <string-name><surname>Casella</surname> <given-names>V</given-names></string-name>, <string-name><surname>Iwabuchi</surname> <given-names>R</given-names></string-name>, <string-name><surname>Fossum</surname> <given-names>E</given-names></string-name>, <string-name><surname>Pedragosa</surname> <given-names>M</given-names></string-name>, <string-name><surname>Castellvi</surname> <given-names>Q</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>XCR1+ DCs are critical for T cell-mediated immunotherapy of chronic viral infections</article-title>. <source>Cell Rep</source>. <year>2023</year>;<volume>42</volume>(<issue>2</issue>):<fpage>112123</fpage>. Epub 2023/02/17. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2023.112123</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">36795562</pub-id>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Deczkowska</surname> <given-names>A</given-names></string-name>, <string-name><surname>David</surname> <given-names>E</given-names></string-name>, <string-name><surname>Ramadori</surname> <given-names>P</given-names></string-name>, <string-name><surname>Pfister</surname> <given-names>D</given-names></string-name>, <string-name><surname>Safran</surname> <given-names>M</given-names></string-name>, <string-name><surname>Li</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>XCR1(+) type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis</article-title>. <source>Nat Med</source>. <year>2021</year>;<volume>27</volume>(<issue>6</issue>):<fpage>1043</fpage>–<lpage>54</lpage>. Epub 2021/05/22. doi: <pub-id pub-id-type="doi">10.1038/s41591-021-01344-3</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">34017133</pub-id>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mysore</surname> <given-names>V</given-names></string-name>, <string-name><surname>Tahir</surname> <given-names>S</given-names></string-name>, <string-name><surname>Furuhashi</surname> <given-names>K</given-names></string-name>, <string-name><surname>Arora</surname> <given-names>J</given-names></string-name>, <string-name><surname>Rosetti</surname> <given-names>F</given-names></string-name>, <string-name><surname>Cullere</surname> <given-names>X</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Monocytes transition to macrophages within the inflamed vasculature via monocyte CCR2 and endothelial TNFR2</article-title>. <source>J Exp Med</source>. <year>2022</year>;<volume>219</volume>(<issue>5</issue>). Epub 2022/04/12. doi: <pub-id pub-id-type="doi">10.1084/jem.20210562</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">35404389</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC9006314</pub-id>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Liao</surname> <given-names>F</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>D</given-names></string-name>, <string-name><surname>Heo</surname> <given-names>GS</given-names></string-name>, <string-name><surname>Leuhmann</surname> <given-names>HP</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Reprogramming alveolar macrophage responses to TGF-beta reveals CCR2+ monocyte activity that promotes bronchiolitis obliterans syndrome</article-title>. <source>J Clin Invest</source>. <year>2022</year>;<volume>132</volume>(<issue>19</issue>). Epub 2022/10/04. doi: <pub-id pub-id-type="doi">10.1172/JCI159229</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">36189800</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC9525120</pub-id>.</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname> <given-names>D</given-names></string-name>, <string-name><surname>An</surname> <given-names>L</given-names></string-name>, <string-name><surname>Moon</surname> <given-names>J</given-names></string-name>, <string-name><surname>Maymi</surname> <given-names>VI</given-names></string-name>, <string-name><surname>McGurk</surname> <given-names>AI</given-names></string-name>, <string-name><surname>Rudd</surname> <given-names>BD</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Ccr2+ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in Braf-Mutant Melanoma</article-title>. <source>Cancer Res</source>. <year>2023</year>;<volume>83</volume>(<issue>14</issue>):<fpage>2328</fpage>–<lpage>44</lpage>. Epub 2023/05/17. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-22-2841</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">37195124</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC10478295</pub-id>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Gu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Chakarov</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bleriot</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kwok</surname> <given-names>I</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>X</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Fate Mapping via Ms4a3-Expression History Traces Monocyte-Derived Cells</article-title>. <source>Cell</source>. <year>2019</year>;<volume>178</volume>(<issue>6</issue>):<fpage>1509</fpage>–<lpage>25.e19</lpage>. Epub 2019/09/07. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2019.08.009</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">31491389</pub-id>.</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bosmans</surname> <given-names>LA</given-names></string-name>, <string-name><surname>van Tiel</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Aarts</surname> <given-names>S</given-names></string-name>, <string-name><surname>Willemsen</surname> <given-names>L</given-names></string-name>, <string-name><surname>Baardman</surname> <given-names>J</given-names></string-name>, <string-name><surname>van Os</surname> <given-names>BW</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages’ transition into a pro-inflammatory state</article-title>. <source>Cardiovasc Res</source>. <year>2023</year>;<volume>119</volume>(<issue>5</issue>):<fpage>1146</fpage>–<lpage>60</lpage>. Epub 2022/05/20. doi: <pub-id pub-id-type="doi">10.1093/cvr/cvac084</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">35587037</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC10202633</pub-id>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mildner</surname> <given-names>A</given-names></string-name>, <string-name><surname>Schonheit</surname> <given-names>J</given-names></string-name>, <string-name><surname>Giladi</surname> <given-names>A</given-names></string-name>, <string-name><surname>David</surname> <given-names>E</given-names></string-name>, <string-name><surname>Lara-Astiaso</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lorenzo-Vivas</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Genomic Characterization of Murine Monocytes Reveals C/EBPbeta Transcription Factor Dependence of Ly6C(-) Cells</article-title>. <source>Immunity</source>. <year>2017</year>;<volume>46</volume>(<issue>5</issue>):<fpage>849</fpage>–<lpage>62 e7</lpage>. Epub 2017/05/18. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2017.04.018</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">28514690</pub-id>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Inui</surname> <given-names>H</given-names></string-name>, <string-name><surname>Nishida</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ichii</surname> <given-names>M</given-names></string-name>, <string-name><surname>Nakaoka</surname> <given-names>H</given-names></string-name>, <string-name><surname>Asaji</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ide</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>XCR1(+) conventional dendritic cell-induced CD4(+) T helper 1 cell activation exacerbates cardiac remodeling after ischemic myocardial injury</article-title>. <source>J Mol Cell Cardiol</source>. <year>2023</year>;<volume>176</volume>:<fpage>68</fpage>–<lpage>83</lpage>. Epub 2023/02/06. doi: <pub-id pub-id-type="doi">10.1016/j.yjmcc.2023.01.011</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">36739942</pub-id>.</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moore</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Tabas</surname> <given-names>I</given-names></string-name></person-group>. <article-title>Macrophages in the pathogenesis of atherosclerosis</article-title>. <source>Cell</source>. <year>2011</year>;<volume>145</volume>(<issue>3</issue>):<fpage>341</fpage>–<lpage>55</lpage>. Epub 2011/05/03. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2011.04.005</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">21529710</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC3111065</pub-id>.</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yoshida</surname> <given-names>T</given-names></string-name>, <string-name><surname>Imai</surname> <given-names>T</given-names></string-name>, <string-name><surname>Kakizaki</surname> <given-names>M</given-names></string-name>, <string-name><surname>Nishimura</surname> <given-names>M</given-names></string-name>, <string-name><surname>Takagi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Yoshie</surname> <given-names>O</given-names></string-name></person-group>. <article-title>Identification of single C motif-1/lymphotactin receptor XCR1</article-title>. <source>The Journal of biological chemistry</source>. <year>1998</year>;<volume>273</volume>(<issue>26</issue>):<fpage>16551</fpage>–<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.273.26.16551</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">9632725</pub-id>.</mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Oliveira</surname> <given-names>CE</given-names></string-name>, <string-name><surname>Gasparoto</surname> <given-names>TH</given-names></string-name>, <string-name><surname>Pinheiro</surname> <given-names>CR</given-names></string-name>, <string-name><surname>Amor</surname> <given-names>NG</given-names></string-name>, <string-name><surname>Nogueira</surname> <given-names>MRS</given-names></string-name>, <string-name><surname>Kaneno</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>CCR5-Dependent Homing of T Regulatory Cells to the Tumor Microenvironment Contributes to Skin Squamous Cell Carcinoma Development</article-title>. <source>Mol Cancer Ther</source>. <year>2017</year>;<volume>16</volume>(<issue>12</issue>):<fpage>2871</fpage>–<lpage>80</lpage>. Epub 2017/09/15. doi: <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-17-0341</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">28904130</pub-id>.</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>He</surname> <given-names>F</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>C</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Tian</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration</article-title>. <source>Signal Transduct Target Ther</source>. <year>2024</year>;<volume>9</volume>(<issue>1</issue>):<fpage>139</fpage>. Epub 2024/05/30. doi: <pub-id pub-id-type="doi">10.1038/s41392-024-01838-9</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">38811552</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC11137111</pub-id>.</mixed-citation></ref>
<ref id="c70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bottcher</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Beyer</surname> <given-names>M</given-names></string-name>, <string-name><surname>Meissner</surname> <given-names>F</given-names></string-name>, <string-name><surname>Abdullah</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Sander</surname> <given-names>J</given-names></string-name>, <string-name><surname>Hochst</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Functional classification of memory CD8(+) T cells by CX3CR1 expression</article-title>. <source>Nat Commun</source>. <year>2015</year>;<volume>6</volume>:<fpage>8306</fpage>. Epub 2015/09/26. doi: <pub-id pub-id-type="doi">10.1038/ncomms9306</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">26404698</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC4667439</pub-id>.</mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chu</surname> <given-names>VT</given-names></string-name>, <string-name><surname>Weber</surname> <given-names>T</given-names></string-name>, <string-name><surname>Graf</surname> <given-names>R</given-names></string-name>, <string-name><surname>Sommermann</surname> <given-names>T</given-names></string-name>, <string-name><surname>Petsch</surname> <given-names>K</given-names></string-name>, <string-name><surname>Sack</surname> <given-names>U</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Efficient generation of Rosa26 knock-in mice using CRISPR/Cas9 in C57BL/6 zygotes</article-title>. <source>BMC Biotechnol</source>. <year>2016</year>;<volume>16</volume>:<fpage>4</fpage>. Epub 2016/01/17. doi: <pub-id pub-id-type="doi">10.1186/s12896-016-0234-4</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">26772810</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC4715285</pub-id>.</mixed-citation></ref>
<ref id="c72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Larson</surname> <given-names>MA</given-names></string-name></person-group>. <article-title>Pronuclear Microinjection of One-Cell Embryos</article-title>. <source>Methods in molecular biology</source>. <year>2020</year>;<volume>2066</volume>:<fpage>27</fpage>–<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-1-4939-9837-1_2</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">31512204</pub-id>.</mixed-citation></ref>
<ref id="c73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Voisinne</surname> <given-names>G</given-names></string-name>, <string-name><surname>Kersse</surname> <given-names>K</given-names></string-name>, <string-name><surname>Chaoui</surname> <given-names>K</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>L</given-names></string-name>, <string-name><surname>Chaix</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Quantitative interactomics in primary T cells unveils TCR signal diversification extent and dynamics</article-title>. <source>Nat Immunol</source>. <year>2019</year>;<volume>20</volume>(<issue>11</issue>):<fpage>1530</fpage>–<lpage>41</lpage>. Epub 2019/10/09. doi: <pub-id pub-id-type="doi">10.1038/s41590-019-0489-8</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">31591574</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC6859066</pub-id>.</mixed-citation></ref>
<ref id="c74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname> <given-names>R</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>G</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>L</given-names></string-name>, <string-name><surname>Fu</surname> <given-names>R</given-names></string-name>, <string-name><surname>Luo</surname> <given-names>J</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Z</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The three members of the Vav family proteins form complexes that concur to foam cell formation and atherosclerosis</article-title>. <source>J Lipid Res</source>. <year>2019</year>;<volume>60</volume>(<issue>12</issue>):<fpage>2006</fpage>–<lpage>19</lpage>. Epub 2019/10/02. doi: <pub-id pub-id-type="doi">10.1194/jlr.M094771</pub-id>. PubMed PMID: <pub-id pub-id-type="pmid">31570505</pub-id>; PubMed Central PMCID: <pub-id pub-id-type="pmcid">PMC6889716</pub-id>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107742.2.sa3</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yona</surname>
<given-names>Simon</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>The Hebrew University of Jerusalem</institution>
</institution-wrap>
<city>Jerusalem</city>
<country>Israel</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Convincing</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
</front-stub>
<body>
<p>This manuscript by Li, Lu et al., presents <bold>important</bold> findings on the role of cDC1 in atherosclerosis and their influence on the adaptive immune system. Using Xcr1Cre-Gfp Rosa26LSL-DTA ApoE-/- mouse models, these data <bold>convincingly</bold> reveal an unexpected, non-redundant role of the XCL1-XCR1 axis in mediating cDC1 contributions to atherosclerosis.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107742.2.sa2</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>In this study by Li et al., the authors re-investigated the role of cDC1 for atherosclerosis progression using the ApoE model. First, the authors confirmed the accumulation of cDC1 in atherosclerotic lesions in mice and humans. Then in order to examine the functional relevance of this cell type, the authors developed a new mouse model to selectively target cDC1. Specifically, they inserted the Cre recombinase directly after the start codon of endogenous XCR1 gene, thereby avoiding off-target activity. Following validation of this model, the authors crossed it with ApoE-deficient mice and found a striking reduction of aortic lesions (numbers and size) following high fat diet. The authors further characterized the impact of cDC1 depletion on lesional T cells and their activation state. Also, they provide in-depth transcriptomic analyses of lesional in comparison to splenic and nodal cDC1. These results imply cellular interactions between lesion T cells and cDC1. Finally, the authors show that the chemokine XCL1, which is produced by activated CD8 T cells (and NK cells) plays a key role for the interaction with XCR1-expressing cDC1 and particularly for the atherosclerotic disease progression.</p>
<p>Strengths:</p>
<p>The surprising results on XCL1 represent a very important gain in knowledge. The role of cDC1 is clarified with a new genetic mouse model.</p>
<p>Comments on revised version:</p>
<p>The authors have addressed my concerns in the revised version of this manuscript.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107742.2.sa1</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>This study investigates the role of cDC1 in atherosclerosis progression using Xcr1Cre-Gfp Rosa26LSL-DTA ApoE-/- mice. The authors demonstrate that selective depletion of cDC1 reduces atherosclerotic lesions in hyperlipidemic mice. While cDC1 depletion did not alter macrophage populations, it suppressed T cell activation (both CD4+ and CD8+ subsets) within aortic plaques. Further, targeting the chemokine Xcl1 (ligand of Xcr1) effectively inhibits atherosclerosis. The manuscript is well-written, and data are clearly presented. The data provided in the article can well support the author's conclusion.</p>
<p>Comments on revised version:</p>
<p>The authors have addressed all previous concerns and made appropriate revisions to the data. I have no further questions.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107742.2.sa0</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Tianhan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lu</surname>
<given-names>Liaoxun</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Qiu</surname>
<given-names>Juanjuan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dong</surname>
<given-names>Xin</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Le</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Kexin</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gu</surname>
<given-names>Yanrong</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Binhui</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jia</surname>
<given-names>Tingting</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lawrence</surname>
<given-names>Toby</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Malissen</surname>
<given-names>Marie</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Guixue</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Rong</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Hui</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Malissen</surname>
<given-names>Bernard</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1340-9342</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Liang</surname>
<given-names>Yinming</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9174-4037</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Lichen</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7810-9941</contrib-id></contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the original reviews.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #1 (Public review):</bold></p>
<p>Summary:</p>
<p>In this study by Li et al., the authors re-investigated the role of cDC1 for atherosclerosis progression using the ApoE model. First, the authors confirmed the accumulation of cDC1 in atherosclerotic lesions in mice and humans. Then, in order to examine the functional relevance of this cell type, the authors developed a new mouse model to selectively target cDC1. Specifically, they inserted the Cre recombinase directly after the start codon of the endogenous XCR1 gene, thereby avoiding off-target activity. Following validation of this model, the authors crossed it with ApoE-deficient mice and found a striking reduction of aortic lesions (numbers and size) following a high-fat diet. The authors further characterized the impact of cDC1 depletion on lesional T cells and their activation state. Also, they provide in-depth transcriptomic analyses of lesional in comparison to splenic and nodal cDC1. These results imply cellular interactions between lesion T cells and cDC1. Finally, the authors show that the chemokine XCL1, which is produced by activated CD8 T cells (and NK cells), plays a key role in the interaction with XCR1-expressing cDC1 and particularly in the atherosclerotic disease progression.</p>
<p>
Strengths:</p>
<p>The surprising results on XCL1 represent a very important gain in knowledge. The role of cDC1 is clarified with a new genetic mouse model.</p>
</disp-quote>
<p>Thank you</p>
<disp-quote content-type="editor-comment">
<p>Weaknesses:</p>
<p>My criticism is limited to the analysis of the scRNAseq data of the cDC1. I think it would be important to match these data with published data sets on cDC1. In particular, the data set by Sophie Janssen's group on splenic cDC1 might be helpful here (PMID: 37172103; <ext-link ext-link-type="uri" xlink:href="https://www.single-cell.be/spleen_cDC_homeostatic_maturation/datasets/cdc1">https://www.single-cell.be/spleen_cDC_homeostatic_maturation/datasets/cdc1</ext-link>). It would be good to assign a cluster based on the categories used there (early/late, immature/mature, at least for splenic DC).</p>
</disp-quote>
<p>Thank you very much for your help. Using the scRNA seq data of Xcr1<sup>+</sup> cDC1 sorted from ApoE<sup>–/–</sup> mice, we re-annotated the populations, following the methodology proposed by Sophie Janssen's group. These results are presented in Figure S9 and Figure S10 and described in detail in the Results and Discussion section.</p>
<p>Please refer to the Results section from line 264 to 284: “Using the scRNA seq data of Xcr1<sup>+</sup> cDC1 sorted from hyperlipidemic mice, we annotated the 10 populations as shown in Figure S9A, following the methodology from a previous study [41]. Ccr7<sup>+</sup> mature cDC1s (Cluster 3, 7 and 9) and Ccr7- immature cDC1s (remaining clusters) were identified across cDC1 cells sorted from aorta, spleen and lymph nodes (Figure S9B). Further stratification based on marker genes reveals that Cluster 10 is the pre-cDC1, with high expression level of CD62L (Sell) and low expression level of CD8a (Figure S9C). Cluster 6 and 8 are the proliferating cDC1s, which express high level of cell cycling genes Stmn1 and Top2a (Figure S9D). Cluster 1 and 4 are early immature cDC1s, and cluster 2 and 5 are late immature cDC1s, according to the expression pattern of Itgae, Nr4a2 (Figure S9E). Cluster 9 cells are early mature cDC1s, with elevated expression of Cxcl9 and Cxcl10 (Figure S9F). Cluster 3 and 7 as late mature cDC1s, characterized by the expression of Cd63 and Fscn1 (Figure S9G). As shown in Figure 5C and Figure S9, the 10 populations displayed a major difference of aortic cDC1 cells that lack in pre-cDC1s (cluster 10) and mature cells (cluster 3, 7 and 9). Interestingly, in hyperlipidemic mice splenic cDC1 possess only Cluster 3 as the late mature cells while the lymph node cDC1 cells have two late mature populations namely Cluster 3 and Cluster 7. In further analysis, we also compared splenic cDC1 cells from HFD mice to those from ND mice. As shown in Figure S10, HFD appears to impact early immature cDC1-1 cells (Cluster 1) and increases the abundance of late immature cDC1 cells (Cluster 2 and 5), regardless of the fact that all 10 populations are present in two origins of samples. We also found that Tnfaip3 and Serinc3 are among the most upregulated genes, while Apol7c and Tifab are downregulated in splenic cDC1 cells sorted from HFD mice”.</p>
<p>Please refer to the Discussion section from line 380 to 385: “Based on the maturation analysis of the cDC1 scRNA seq data [41], our findings suggest that the aortic cDC1 cells display a major difference from those of spleen and lymph nodes by lacking the mature clusters, whereas lymph node cDC1 cells contain an additional Fabp5<sup>+</sup> S100a4<sup>+</sup> late mature Cluster. Our results also suggest that hyperlipidemia contributes to alteration in early immature cDC1 and in the abundance of late immature cDC1 cells, which was associated with dramatic change in gene expression of Tnfaip3, Serinc3, Apol7c and Tifab”.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Public review):</bold></p>
<p>This study investigates the role of cDC1 in atherosclerosis progression using Xcr1Cre-Gfp Rosa26LSL-DTA ApoE-/- mice. The authors demonstrate that selective depletion of cDC1 reduces atherosclerotic lesions in hyperlipidemic mice. While cDC1 depletion did not alter macrophage populations, it suppressed T cell activation (both CD4+ and CD8+ subsets) within aortic plaques. Further, targeting the chemokine Xcl1 (ligand of Xcr1) effectively inhibits atherosclerosis. The manuscript is well-written, and the data are clearly presented. However, several points require clarification:</p>
<p>(1) In Figure 1C (upper plot), it is not clear what the Xcr1 single-positive region in the aortic root represents, or whether this is caused by unspecific staining. So I wonder whether Xcr1 single-positive staining can reliably represent cDC1. For accurate cDC1 gating in Figure 1E, Xcr1+CD11c+ co-staining should be used instead.</p>
</disp-quote>
<p>The observed false-positive signal in the wavy structures within immunofluorescence Figure 1C (upper panel) results from the strong autofluorescence of elastic fibers, a major vascular wall component (alongside collagen). This intrinsic property of elastic fibers is a well-documented confounder in immunofluorescence studies [A, B].</p>
<p>In contrast, immunohistochemistry (IHC) employs an enzymatic chromogenic reaction (HRP with DAB substrate) that generates a brown precipitate exclusively at antigen-antibody binding sites. Importantly, vascular elastic fibers lack endogenous enzymatic activity capable of catalyzing the DAB reaction, thereby preventing this source of false positivity in IHC.</p>
<p>Given that Xcr1 is exclusively expressed on conventional type 1 dendritic cells [C], and considering that IHC lacks the multiplexing capability inherent to immunofluorescence for antigen co-localization, single-positive Xcr1 staining reliably identifies cDC1s in IHC results.</p>
<p>[A] König, K et al. “Multiphoton autofluorescence imaging of intratissue elastic fibers.” Biomaterials vol. 26,5 (2005): 495-500. doi:10.1016/j.biomaterials.2004.02.059</p>
<p>[B] Andreasson, Anne-Christine et al. “Confocal scanning laser microscopy measurements of atherosclerotic lesions in mice aorta. A fast evaluation method for volume determinations.” Atherosclerosis vol. 179,1 (2005): 35-42. doi:10.1016/j.atherosclerosis.2004.10.040</p>
<p>[C] Dorner, Brigitte G et al. “Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells.” Immunity vol. 31,5 (2009): 823-33. doi:10.1016/j.immuni.2009.08.027</p>
<disp-quote content-type="editor-comment">
<p>(2) Figure 4D suggests that cDC1 depletion does not affect CD4+/CD8+ T cells. However, only the proportion of these subsets within total T cells is shown. To fully interpret effects, the authors should provide:</p>
<p>(a) Absolute numbers of total T cells in aortas.</p>
<p>(b) Absolute counts of CD4+ and CD8+ T cells.</p>
</disp-quote>
<p>Thanks for your suggestions. We agree that assessing both proportions and absolute numbers in Figure 4 provides a more complete picture of the effects of cDC1 depletion on T cell populations. Furthermore, we also add the absolute count of cDC1 cells and total T cells, and CD44 MFI (mean fluorescence intensity) in CD4<sup>+</sup> and CD8<sup>+</sup> T cells in Figure 4, and supplemented corresponding textual descriptions in the revised manuscript.</p>
<p>Please refer to the Results section from line 183 to 187: “Subsequently, we assessed T cell phenotype in the two groups of mice. While neither the frequencies nor absolute counts of aortic CD4<sup>+</sup> and CD8<sup>+</sup> T cells differed significantly between two groups of mice (Figure 4D-F), CD69 frequency and CD44 MFI (Mean Fluorescence Intensity), the T cell activation markers, were significantly reduced in both CD4<sup>+</sup> and CD8<sup>+</sup> T cells from Xcr1<sup>+</sup> cDC1 depleted mice compared to controls (Figure 4G and H)”.</p>
<disp-quote content-type="editor-comment">
<p>(3) How does T cell activation mechanistically influence atherosclerosis progression? Why was CD69 selected as the sole activation marker? Were other markers (e.g., KLRG1, ICOS, CD44) examined to confirm activation status?</p>
</disp-quote>
<p>We sincerely appreciate these insightful comments. As extensively documented in the literature, activated effector T cells (both CD4+ and CD8+) critically promote plaque inflammation and instability through their production of pro-inflammatory cytokines (particularly IFN-γ and TNF-α), which drive endothelial activation, exacerbate macrophage inflammatory responses, and impair smooth muscle cell function [A].</p>
<p>In our study, we specifically investigated the role of cDC1 cells in atherosclerosis progression. Our key findings demonstrate that cDC1 depletion attenuates T cell activation (as shown by reduced CD69/CD44 expression) and that this reduction in activation is functionally linked to the observed decrease in atherosclerosis burden in our model.</p>
<p>Regarding CD44 as an activation marker, we performed quantitative analyses of CD44 mean fluorescence intensity (MFI) in aortic T cells (Figure 4). Importantly, the MFI of CD44 was significantly lower on both CD4+ and CD8+ T cells from Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>–/–</sup> mice compared to the control ApoE<sup>–/–</sup> mice (data shown below), which is consistent with the result of CD69 in Figure 4. We added the related description in the Result section.</p>
<p>Please refer to the Results section from line 185 to 187 “CD69 frequency and CD44 MFI (Mean Fluorescence Intensity), the T cell activation markers, were significantly reduced in both CD4+ and CD8+ T cells from Xcr1+ cDC1 depleted mice compared to controls (Figure 4G and H)”.</p>
<p>Similarly, MFI of CD44 was significantly lower on both CD4<sup>+</sup> and CD8<sup>+</sup> T cells from Xcl1<sup>–/–</sup> ApoE<sup>–/–</sup> mice compared to the control ApoE<sup>–/–</sup> mice (data shown below), which is consistent with the result of CD69 in Figure 7. We also added the related description in the Result section.</p>
<p>Please refer to the Results section from line 308 to 309 “Crucially, CD69<sup>+</sup> frequency and CD44 MFI remained comparable in both aortic CD4<sup>+</sup> and CD8<sup>+</sup> T cells between two groups (Figure 7D-F).”</p>
<p>[A] Hansson, Göran K, and Andreas Hermansson. “The immune system in atherosclerosis.” Nature immunology vol. 12,3 (2011): 204-12. doi:10.1038/ni.2001</p>
<disp-quote content-type="editor-comment">
<p>(4) Figure 7B: Beyond cDC1/2 proportions within cDCs, please report absolute counts of: Total cDCs, cDC1, and cDC2 subsets. Figure 7D: In addition to CD4+/CD8+ T cell proportions, the following should be included:</p>
<p>(a) Total T cell numbers in aortas</p>
<p>(b) Absolute counts of CD4+ and CD8+ T cells.</p>
</disp-quote>
<p>Thanks for your suggestions. We have now included in Figure 7 the absolute counts of cDC, cDC1, and cDC2 cells, along with CD4<sup>+</sup> and CD8<sup>+</sup> T cells in aortic tissues. Additionally, we provide the corresponding CD44 mean fluorescence intensity (MFI) measurements for both CD4<sup>+</sup> and CD8<sup>+</sup> T cell populations. We added the related description in the Result section.</p>
<p>Please refer to the Results section from line 303 to 311: “The flow cytometric results illustrated that both frequencies and absolute counts of Xcr1<sup>+</sup> cDC1 cells in the aorta were significantly reduced, but cDCs and cDC2 cells from Xcl1<sup>–/–</sup> ApoE<sup>–/–</sup> were comparable with that from ApoE<sup>–/–</sup> (Figure 7A-C). Moreover, in both lymph node and spleen, the absolute numbers of pDC, cDC1 and cDC2 from Xcl1<sup>–/–</sup> ApoE<sup>–/–</sup> were comparable with that from ApoE<sup>–/–</sup> (Figure S11). Crucially, CD69<sup>+</sup> frequency and CD44 MFI remained comparable in both aortic CD4<sup>+</sup> and CD8<sup>+</sup> T cells between two groups (Figure 7D-F). However, aortic CD8<sup>+</sup> T cells exhibited reduced frequency and absolute count, while CD4<sup>+</sup> T cells showed increased frequency but unchanged counts in Xcl1<sup>–/–</sup> ApoE<sup>–/–</sup> mouse versus controls (Figure 7G and H).”</p>
<disp-quote content-type="editor-comment">
<p>(5) cDC1 depletion reduced CD69+CD4+ and CD69+CD8+ T cells, whereas Xcl1 depletion decreased Xcr1+ cDC1 cells without altering activated T cells. How do the authors explain these different results? This discrepancy needs explanation.</p>
</disp-quote>
<p>We sincerely appreciate your professional and insightful comments regarding the mechanistic relationship between cDC1 depletion and T cell activation. Direct cDC1 depletion in the Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>–/–</sup> micmodel removes both recruited and tissue-resident cDC1s, eliminating their multifunctional roles in antigen presentation, co-stimulation and cytokine secretion essential for T cell activation. In contrast, Xcl1 depletion reduces, but does not eliminate cDC1 migration into plaques. Furthermore, alternative chemokine axes (e.g., CCL5/CCR5, CXCL9/CXCR3, BCL9/BCL9L) may partially rescue cDC1 recruitment [13, 68, 69], and non-cDC1 APCs (e.g., monocytes, cDC2s) may compensate for T cell activation [55, 70]. We emphasize that Xcl1 depletion specifically failed to alter T cell activation in hyperlipidemic ApoE<sup>–/–</sup> mice. However, its impact may differ in other pathophysiological contexts due to compensatory mechanisms. We thank you again for highlighting this nuance, which strengthens our mechanistic interpretation. We have added these points to the discussion section and included new references.</p>
<p>Please refer to the Discussion section from line 407 to 413: “Notably, while complete ablation of Xcr1<sup>+</sup> cDC1s impaired T cell activation, reduction of Xcr1<sup>+</sup> cDC1 recruitment via Xcl1 deletion did not significantly compromise this process. This discrepancy may arise through compensatory mechanisms: alternative chemokine axes (e.g., CCL5/CCR5, CXCL9/CXCR3, BCL9/BCL9L) may partially rescue Xcr1<sup>+</sup> cDC1 homing [13, 68, 69], while non-cDC1 antigen-presenting cells (e.g., monocytes, cDC2s) may sustain T cell activation [55, 70]. Furthermore, tissue-specific microenvironment factors could potentially modulate its role in other diseases.”. [13] Eisenbarth, S C. “Dendritic cell subsets in T cell programming: location dictates function.” Nature reviews. Immunology vol. 19,2 (2019): 89-103. doi:10.1038/s41577-018-0088-1 [55] Brewitz, Anna et al. “CD8+ T Cells Orchestrate pDC-XCR1+ Dendritic Cell Spatial and Functional Cooperativity to Optimize Priming.” Immunity vol. 46,2 (2017): 205-219. doi:10.1016/j.immuni.2017.01.003 [68] de Oliveira, Carine Ervolino et al. “CCR5-Dependent Homing of T Regulatory Cells to the Tumor Microenvironment Contributes to Skin Squamous Cell Carcinoma Development.” Molecular cancer therapeutics vol. 16,12 (2017): 2871-2880. doi:10.1158/1535-7163.MCT-17-0341.[69] He F, Wu Z, Liu C, Zhu Y, Zhou Y, Tian E, et al. Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration. Signal Transduct Target Ther. 2024;9(1):139. Epub 2024/05/30. doi: 10.1038/s41392-024-01838-9. PubMed PMID: 38811552; PubMed Central PMCID: PMC11137111.[70] Böttcher, Jan P et al. “Functional classification of memory CD8(+) T cells by CX3CR1 expression.” Nature communications vol. 6 8306. 25 Sep. 2015, doi:10.1038/ncomms9306.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #1 (Recommendations for the authors):</bold></p>
<p>(1) Line 32 - The authors might want to add that the mouse model leads to a &quot;constitutive&quot; depletion of cDC1.</p>
</disp-quote>
<p>Thanks for your advice, we have revised the sentence as follows.</p>
<p>Please refer to the Results section from line 31 to 33: “we established Xcr1<sup>Cre-Gfp</sup> Rosa26<sup>LSL-DTA</sup> ApoE<sup>–/–</sup> mice, a novel and complex genetic model, in which cDC1 was constitutively depleted in vivo during atherosclerosis development”.</p>
<disp-quote content-type="editor-comment">
<p>(2) Line 187-188: The authors claim that T cell activation was &quot;inhibited&quot; if cDC1 was depleted. The data shows that the T cells were less activated, but there is no indication of any kind of inhibition; this should be corrected.</p>
</disp-quote>
<p>Thanks for your advice, we have revised the sentence as follows.</p>
<p>Please refer to the Results section from line 183 to 187: “Subsequently, we assessed T cell phenotype in the two groups of mice. While neither the frequencies nor absolute counts of aortic CD4<sup>+</sup> and CD8<sup>+</sup> T cells differed significantly between two groups of mice (Figure 4D-F), CD69 frequency and CD44 MFI (Mean Fluorescence Intensity), the T cell activation markers, were significantly reduced in both CD4<sup>+</sup> and CD8<sup>+</sup> T cells from Xcr1<sup>+</sup> cDC1 depleted mice compared to controls (Figure 4G and H)”.</p>
<disp-quote content-type="editor-comment">
<p>(3) Why are some splenic DC clusters absent in LNs and vice versa? This is not obvious to this reviewer and should at least be discussed.</p>
</disp-quote>
<p>We appreciate the insightful question regarding the absence of certain splenic DC clusters in LNs. This phenomenon in Figure 5 aligns with the 'division of labor' paradigm in dendritic cell biology: tissue microenvironments evolve specialized DC subsets to address local immunological challenges. The absence of universal clusters reflects functional adaptation, not technical artifacts. We acknowledge that this tissue-specific heterogeneity warrants further discussion and have expanded our analysis to address this point in the discussion part of our manuscript.</p>
<p>Please refer to the Discussion section from line 375 to 385: “This pronounced tissue-specific compartmentalization of Xcr1<sup>+</sup> cDC1 subsets may related to multiple mechanisms including developmental imprinting that instructs precursor differentiation into transcriptionally distinct subpopulations [62], and microenvironmental filtering through organ-specific chemokine axes (e.g., CCL2/CCR2 in spleen) selectively recruits receptor-matched subsets [63, 64]. This spatial specialization optimizes pathogen surveillance for local immunological challenges. Based on the maturation analysis of the cDC1 scRNA seq data [41], our findings suggest that the aortic cDC1 cells display a major difference from those of spleen and lymph nodes by lacking the mature clusters, whereas lymph node cDC1 cells contain an additional Fabp5<sup>+</sup> S100a4<sup>+</sup> late mature Cluster. Our results also suggest that hyperlipidemia contributes to alteration in early immature cDC1 and in the abundance of late immature cDC1 cells, which was associated with dramatic change in gene expression of Tnfaip3, Serinc3, Apol7c and Tifab”.</p>
<p>[62]. Liu Z, Gu Y, Chakarov S, Bleriot C, Kwok I, Chen X, et al. Fate Mapping via Ms4a3-Expression History Traces Monocyte-Derived Cells. Cell. 2019;178(6):1509-25 e19. Epub 2019/09/07. doi: 10.1016/j.cell.2019.08.009. PubMed PMID: 31491389.</p>
<p>[63]. Bosmans LA, van Tiel CM, Aarts S, Willemsen L, Baardman J, van Os BW, et al. Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages' transition into a pro-inflammatory state. Cardiovasc Res. 2023;119(5):1146-60. Epub 2022/05/20. doi: 10.1093/cvr/cvac084. PubMed PMID: 35587037; PubMed Central PMCID: PMC10202633.</p>
<p>[64]. Mildner A, Schonheit J, Giladi A, David E, Lara-Astiaso D, Lorenzo-Vivas E, et al. Genomic Characterization of Murine Monocytes Reveals C/EBPbeta Transcription Factor Dependence of Ly6C(-) Cells. Immunity. 2017;46(5):849-62 e7. Epub 2017/05/18. doi: 10.1016/j.immuni.2017.04.018. PubMed PMID: 28514690.</p>
<p>[41]. Bosteels V, Marechal S, De Nolf C, Rennen S, Maelfait J, Tavernier SJ, et al. LXR signaling controls homeostatic dendritic cell maturation. Sci Immunol. 2023;8(83):eadd3955. Epub 2023/05/12. doi: 10.1126/sciimmunol.add3955. PubMed PMID: 37172103.</p>
<disp-quote content-type="editor-comment">
<p>(4) The authors should discuss how XCL1 could impact lesional cDC1 and T cell abundance. Notably, preDCs do not express XCR1, and T cells express XCL1 following TCR activation. Is there a recruitment or local proliferation defect of cDC1 in the absence of XCL1? Could there also be a role for NK cells as a potential source of XCL1?</p>
</disp-quote>
<p>We appreciate your insightful questions regarding the differential effects of Xcl1 on cDC1s and T cells. Xcl1 primarily mediates the recruitment of mature cDC1s. Our data demonstrate that Xcl1 deletion significantly reduces aortic cDC1 abundance, which correlates with a concomitant decrease in CD8<sup>+</sup> T cell numbers within the aorta. These findings strongly suggest that the Xcl1-Xcr1 axis plays a regulatory role in T cell accumulation in aortic plaques.</p>
<p>Consistent with prior studies [A, B], cDC1 recruitment can occur in the absence of Xcl1 which echoes our findings that cDC1 cells were still found in Xcl1 knockout aortic plaque but in lower abundance. It is very true that further studies are required to address how the Xcl1 dependent and independent cDC1 cells activate T cells and if they possess capability of proliferation in tissue differentially. We have added these points in discussion section.</p>
<p>Please refer to the Discussion section from line 407 to 415: “Notably, while complete ablation of Xcr1<sup>+</sup> cDC1s impaired T cell activation, reduction of Xcr1<sup>+</sup> cDC1 recruitment via Xcl1 deletion did not significantly compromise this process. This discrepancy may arise through compensatory mechanisms: alternative chemokine axes (e.g., CCL5/CCR5, CXCL9/CXCR3, BCL9/BCL9L) may partially rescue Xcr1<sup>+</sup> cDC1 homing [13, 68, 69], while non-cDC1 antigen-presenting cells (e.g., monocytes, cDC2s) may sustain T cell activation [55, 70]. Furthermore, tissue-specific microenvironment factors could potentially modulate its role in other diseases. In summary, our findings identify Xcl1 as a potential therapeutic target for atherosclerosis therapy, though its cellular origins and regulation of lesional Xcr1<sup>+</sup> cDC1 and T cells dynamics require further studies”.</p>
<p>In literatures, Xcl1 are expressed in NK cells and subsects of T cells, and NK cells can be a potential source of Xcl1 during atherosclerosis which deserve further investigations [A, C, D].</p>
<p>[A] Böttcher, Jan P et al. “NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.” Cell vol. 172,5 (2018): 1022-1037.e14. doi:10.1016/j.cell.2018.01.004</p>
<p>[B] He, Fenglian et al. “Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration.” Signal transduction and targeted therapy vol. 9,1 139. 29 May. 2024, doi:10.1038/s41392-024-01838-9</p>
<p>[C] Woo, Yeon Duk et al. “The invariant natural killer T cell-mediated chemokine X-C motif chemokine ligand 1-X-C motif chemokine receptor 1 axis promotes allergic airway hyperresponsiveness by recruiting CD103+ dendritic cells.” The Journal of allergy and clinical immunology vol. 142,6 (2018): 1781-1792.e12. doi:10.1016/j.jaci.2017.12.1005</p>
<p>[D] Winkels, Holger et al. “Atlas of the Immune Cell Repertoire in Mouse Atherosclerosis Defined by Single-Cell RNA-Sequencing and Mass Cytometry.” Circulation research vol. 122,12 (2018): 1675-1688. doi:10.1161/CIRCRESAHA.117.312513</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Recommendations for the authors):</bold></p>
<p>There is a logical error in line 298. I suggest revising to: &quot;Collectively, these data suggest that Xcl1 promotes atherosclerosis by recruiting Xcr1+ cDC1 cells, which subsequently drive T cell activation in lesions.&quot;</p>
</disp-quote>
<p>Thanks for your advice. Since Xcl1 deficiency reduced both the frequencies and absolute counts of Xcr1+ cDC1 and CD8+ T cells in lesions without affecting T cell activation, we revised the sentence as you suggested.</p>
<p>Please refer to the Results section from line 314 to 315: “Collectively, these data suggest that Xcl1 promotes atherosclerosis by recruiting Xcr1<sup>+</sup> cDC1 cells, and facilitating CD8<sup>+</sup> T cell accumulation in lesions”.</p>
</body>
</sub-article>
</article>